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ABSTRACT
Amyotrophic lateral sclerosis [ALS] is a neurological disease characterized by the selective loss of motor neurons [MNs] and death due to respiratory failure usually occurs within 3-5 years of symptom onset. Mutations in the genes encoding TAR DNA binding protein of 43 kDa [TDP-43], fused in sarcoma/translocated in liposarcoma [FUS/TLS] and Cu/Zn superoxide dismutase [SOD1] have all been associated with ALS. Never before has a link been made between the variant of ALS and intraneuronal pathology. This thesis has sought to (1) analyze the immunohistochemical expression of TDP-43, FUS/TLS, SOD1, Rho Guanine nucleotide exchange factor [RGNEF], and 5 other ALS-associated proteins across multiple variants of ALS, and (2) characterize the immunohistochemical expression of RGNEF for the first time. Here, I show that mutant SOD1-ALS is a pathologically unique variant of ALS. This finding may be used in the identification of novel families that may be at risk for developing ALS.
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Amyotrophic lateral sclerosis [ALS] is a progressive, fatal neurodegenerative disease that involves the selective loss of motor neurons [MNs] of the brain, brainstem, and spinal cord (Logroscino et a l, 2008). The death of increasing numbers of MNs leads to muscle paralysis and the arrest of most voluntary movements. The median survival for patients with ALS is 3 to 5 years following symptom onset, and death most often comes as a result of respiratory failure. The only pharmaceutical that has been approved after a Phase 111 study for the treatment of ALS is riluzole, which is an inhibitor of glutamate excitotoxicity (Bensimon et al., 1994). By delaying the introduction of assisted ventilation, it is known to slow the progression of ALS and increase survival by 3 to 5 months in many patients. With this exception, the management of ALS is palliative and care is focused on symptom relief. There are currently about 3,000 patients across Canada that are living with ALS, and for every new diagnosis, someone dies as a result of the disease [ALS Society of Canada, 2011).
Approximately 90% of ALS cases are sporadic [sALS], while the remaining 10% are familial [fALS]. There are currently 13 known genetic variants of the disease that are largely indistinguishable from one another with respect to clinical phenotype. The mutations that are of major importance to this thesis are in the genes encoding superoxide dismutase 1 [SODI], TAR-DNA
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binding protein of 43 kDa [TDP-43], and fused in sarcoma/translocated in liposarcoma [FUS/TLS].
If permission is granted to perform an autopsy when an individual affected by ALS dies, a neuropathologist will validate the diagnosis by microscopic examination of brain and spinal cord tissue. Working with a colleague [Dr. Rosa Radamakers], we evaluated our reservoir of cases for known ALS-associated genetic mutations. Eight percent of cases that were previously thought to be sporadic in origin were found to harbour mutations in either SOD1, TARDBP, or FUS/TLS. In this thesis, I have examined whether spinal cord motor neuron pathology would allow neuropathologists to differentiate the variants of ALS and direct clinicians and researchers to screen patients for new mutations and the possible identification of novel families that may be affected by fALS. Specifically, I have studied the expression of SOD1, TDP-43, FUS/TLS, Rho-Guanine nucleotide exchange factor [RGNEF], phosphorylated high molecular weight neurofilament [pNFH], peripherin, ubiquitin, sequestosome 1 [p62], and optineurin across a panel of cases containing cases of mutant [mt] S0D1-ALS, mtTDP-43-ALS, mtFUS/TLS-ALS, fALS without any known mutations, sALS without any known mutations and neuropathologically normal controls. In doing so, I have tested the hypothesis that all variants o f ALS are pathologically distinct and can be differentiated 
by spinal cord pathology using a panel of contemporary ALS-associated
markers.
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As I will show, there are changes in the expression patterns of several RNA binding proteins as well as several other ALS-associated proteins across the variants of ALS that I have tested. In addition, I will show that cases of mtSODl-ALS have distinct neuropathological characteristics when compared with other genetic variants of the disease as well as with cases of sALS and fALS without any known mutations. This leads me to propose that mtSODl-ALS [ALS 1] is a pathologically unique variant of the disease and may possess a unique disease pathophysiology.
History and Epidemiology of ALS
First described by the French neurologist known as the "founder of modern neurology" Jean-Martin Charcot [Charcot and Joffroy, 1869], ALS is classified based on a patient’s family history or their habituation within certain hyperendemic foci of ALS. The first and most common form of ALS, sALS, accounts for approximately 90% of cases. It is most commonly seen in adulthood with a peak age of onset in the 6th decade of life (Shoesmith and Strong, 2006]. Juvenile forms of the disease are recognized, however, and onset under the age of 20 does occur (Gouveia and de Carvalho, 2007]. In addition to sALS, approximately 10% of cases come from families with a known history of the disease and are appropriately termed fALS.
There is also a Western Pacific variant of ALS that accounts for a small percentage of cases. This affects people from Guam, the Marianas archipelago of
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Micronesia and the Kii peninsula of Japan, and is thought to have an environmental cause. There are currently 2 hypotheses that could explain the increased incidence of ALS in these regions. The first is the presence of (3- methylamino-L-alanine [BMAA], a neurotoxin found in the seeds of the cycad, a traditional food staple in the region (Garruto, 2006). The second hypothesis involves neurotoxicity due to the deposition of metals within MNs. This is thought to occur due to a defect in mineral metabolism causing a form of secondary hyperparathyroidism. This is provoked by a chronic nutritional deficiency of environmental calcium and magnesium, which causes an increased gastrointestinal absorption of aluminum and the ultimate neuronal metal deposition (Garruto, 2006). The incidence of the Western Pacific variant of ALS has been decreasing in recent years, which has been attributed to a changing diet due to the Westernization of the region’s culture following World War II (Spencer et a l, 1987).
ALS is the most common MN disease diagnosis. The worldwide incidence ranges between 1.89 and 1.91 per 100,000 and has a prevalence of approximately 8 per 100,000 (Worms, 2001). There is a gender bias amongst ALS patients with a male-to-female ratio of 1.4:1, but this seems to approach unity after the age of 70 (Shoesmith and Strong, 2006). Recent evidence, however, suggests that the phenomenon of a gender bias is disappearing (Logroscino et a l, 2008; Zoccolella et al., 2008). Over one’s lifetime, the estimated risk of acquiring ALS ranges from 1 in 1,000 (Traynor et al., 1999) to 1 in 400 (Johnston e ta l, 2006).
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Disease Course and Clinical Spectrum
Death from ALS usually comes as a result of respiratory failure, and usually comes within 3 to 5 years of symptom onset. The first signs of ALS can help physicians to provide a prognosis with respect to the rate of progression. Patients with bulbar onset ALS, in which motor problems first start affecting speech and swallowing, experience a more aggressive disease course with a median survival of 2-3 years, whereas patients presenting with limb onset ALS have a longer survival median of 3-5 years (Logroscino et a l, 2008). Survival longer than 5 years is uncommon; the number of those affected managing to survive longer than 5 years ranges from 23-28% (Strong et a l, 1991; Chancellor 
et a l, 1993; Testa et a l, 2004). Survival longer than 10 years does occur; however, only in approximately 4% of cases (Turner et a l, 2002). As death due to respiratory failure is common, patients often require assisted ventilation in the final stages of the disease (Shoesmith and Strong, 2006).
The diagnosis of ALS is based on the El Escorial criteria as defined at "The Clinical Limits of ALS” conference in El Escorial, Spain, 29-31 May 1990. A definitive clinical diagnosis of ALS includes 3 criteria: (1) evidence of upper motor neuron [UMN] degeneration, (2) evidence of lower motor neuron [LMN] degeneration, and (3) progression (Brooks, 1994). The finding of LMN degeneration can be supported by electromyography. Signs of UMNdegeneration include spasticity, hyperreflexia, and rigidity, while signs of LMN degeneration include fasciculations, weakness, hypotonia and eventual
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muscular atrophy and paralysis. To be diagnosed with ALS, it is important to ensure the absence of any other disease process that may mimic ALS. Even with evidence to diagnose a case as clinically definite, a post-mortem neuropathological exam is required to establish absolute certainty. Although the traditional view of ALS has been one in which cognitively intact patients lose motor function, an increasing finding is the presence of both ALS and a frontotemporal syndrome.
Increasingly, ALS is being regarded as a multisystems disorder with non­motor manifestations in addition to the progressive loss of motor function. There are currently 4 accepted classifications for patients suffering from frontotemporal impairment concomitantly with ALS. The 2 most commonly seen diagnoses are ALS with cognitive impairment [ALSci] and ALS with behavioural impairment [ALSbi], which generally encompass mild to moderate frontotemporal impairment. ALS-frontotemporal dementia [ALS-FTD] describes the fulfillment of the Neary criteria for FTD (Neary et a l, 1998) in addition to ALS. Finally, ALS-dementia describes, in addition to ALS, the presence of dementia that does not fit the above criteria, such as concomitant Alzheimer's disease or vascular dementia (Strong, 2008). Estimates of cognitive impairment in addition to the motor manifestations typical of ALS range from 3- 52% (Strong, 2008), but cases of ALSci and ALSbi have been identified in greater than 50% of patients through neuropsychological testing, with ALS-FTD representing a small fraction of those (Woolley and Jonathan, 2008). In order to establish consensus criteria for the diagnosis of frontotemporal syndromes in
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ALS patients, a conference was held in London, Canada in June 2007. Due to this conference, there are now recognized criteria for the identification of non­motor manifestations in ALS patients [Strong et a l, 2009]. It is hoped that this will help in the development of novel therapies for cognitive impairment in ALS. Recently, evidence has suggested that administration of lithium to individuals with ALS may stop progression of cognitive impairment [Rush et a l, 2010). Further work into the efficacy of lithium treatment on cognitive impairment needs to be done, but current results seem promising.
Genetics of ALS
As discussed, approximately 10% of ALS cases are familial. Because the hypothesis on which this thesis is based assumes an understanding of the genetic variants of ALS, what follows is a discussion regarding the known genetic linkages to ALS. A complete list of presently known gene associations is presented in Table 1.1: Genetic Variants of ALS.
Approximately 20% of fALS cases are associated with mutations in the 
SOD1 gene on chromosome 21 and are known as ALS 1 [Rosen et a l, 1993). SOD1 is a 153-amino acid metalloenzyme that forms a homodimer and whose function is to convert toxic superoxide free radicals to H2O2, which can then be removed from the cell by other enzymes [Shaw, 2005). To date, there are 153 known SOD1 mutations that have been associated with ALS [Felbecker et a l, 2010). The majority of these mutations are clustered around the edges of the
9
Genetic Inheritance Chromosome Gene AlternativeVariant Pattern Locus Phenotype
ALS 1 Dominant 21q22.1 SODI None
ALS 2 Recessive 2q33 Alsin Infantile spastic, juvenile PLSALS 3 Dominant 18q21 Unknown None
ALS 4 Dominant 9q34 SETX CMT ordHMN
ALS 5 Recessive 15ql5.1-q21.1 Unknown None
ALS 6 Dominant 16ql2 FUS/TLS None
ALS 7 Dominant 20pl3 Unknown None
ALS 8 Dominant 20ql3.33 VAPB Late onset SMA
ALS 9 Dominant 1 4 q ll ANG/VEGF None
ALS 10 Dominant lp36.2 TARDBP Possible FTD
ALS 11 Dominant 6q21 FIG4 None
ALS 12 Dominant/Recessive 10pl5-pl4 OPTN NoneALS-FTD Dominant 17q21.1 MAPT Disinhibition,dementia
Table 1.1: Genetic Variants of ALS (Strong, 2010; Ticozzi é ta l, 2011)
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protein’s |3 barrel, within the dimer interface, or near one of the zinc-binding superoxide dismutase pockets (Beckman et a l, 2001). Many of these mutations are known to affect interactions that are critical to the structural integrity of S O D l’s P barrel (Deng et al., 1993). The toxicity of mutant [mt] SOD1 is thought to occur due to a toxic gain-of-function mechanism, which is achieved when Zn2+ is lost from SOD1. This is sufficient to cause MN cell death (Estevez et al., 1999). Although wild-type S0D1 cannot bind RNA, mtSODl has been shown to interact with RNA and act as a destabilizer (Ge et a l, 2005). In addition to being linked to fALS, mutant forms of S0D1 have been shown to be associated with sALS (Robberecht et al., 1996). Interestingly, different SOD1 mutations have different clinical manifestations with respect to survival following diagnosis. For example, patients with the common A4V mutation experience an aggressive disease course with a survival median of 1.4 years, whereas patients expressing the G37R mutation commonly approach 20 years survival (Cudkowicz et al., 1997).
ALS 10 is caused by mutations in TARDBP, the gene encoding TDP-43. Since the discovery of TDP-43-positive ubiquitinated neuronal cytoplasmic inclusions [NCIs] in ALS tissue (Arai et a l, 2006; Neumann et al., 2006), much work in the ALS field has centered on the role of TDP-43 in ALS pathogenesis. Since 2008, many TARDBP mutations have been found (Kabashi et a l, 2008; Kuhnlein et al., 2008; Rutherford et a l, 2008; Sreedharan et al., 2008; Van Deerlin et al., 2008; Corrado et al., 2009; Daoud et al., 2009; Del Bo et al., 2009). There are currently 30 known distinct mutations that have been associated with
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ALS in 22 unrelated families and in 29 sporadic cases of ALS (Lagier-Tourenne and Cleveland, 2009; Perry et al., 2010). The majority of TARDBP mutations are missense mutations that can be mapped to the glycine-rich, C-terminus of the protein, and therefore would be predicted to affect protein-protein interactions.
ALS 6 is caused by mutations in the gene encoding FUS/TLS. The FUS/TLS protein is a 526 amino acid protein encoded for by 15 exons. It is characterized by distinct motifs including: an N-terminal serine-tyrosine- glutamine-glycine-rich region [QGSY region], a glycine-rich region, an RNA- recognition motif [RRM], multiple RGG repeats involved in RNA binding, a C- terminus zinc finger, and a highly conserved extreme C-terminal region (Lagier- Tourenne and Cleveland, 2009). Recently, FUS/TLS was found to harbour mutations that are associated with fALS (Kwiatkowski et al., 2009; Vance et al., 2009), the majority of which are missense and cluster in the extreme C- terminus [aa514-525] (Perry et al., 2010). In addition to the C-terminus mutations, there are 2 mutations of note in the glycine-rich region of FUS/TLS, both of which correspond to an insertion or deletion of 2 glycines (Lagier- Tourenne and Cleveland, 2009).
Although less directly related to this thesis, many other known forms of fALS have been attributed to mutations in specific genes. ALS 2, for example, occurs due to mutations in the gene encoding alsin (Yang et al., 2001). A rare autosomal dominant form of juvenile ALS [ALS 4] is associated with mutations in the gene encoding senataxin [SETX] (Chen et al., 2004). ALS 8 is used to
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describe ALS associated with mutations in the gene encoding vesicle-associated membrane protein B [VAPB] (Nishimura et a l, 2004). Vascular endothelial growth factor [VEGF] mutations have been shown to lead to sequence variations that have biological effects in ALS and have been found in families, thus the label of ALS 9 (Lambrechts et al., 2003; Greenway et a l, 2004). Mutations have been found in the FIG4 gene in 6 sALS and 3 fALS patients (Chow et a l, 2007). Mutations have also been reported in the gene encoding optineurin in 4 Japanese consanguineous kindreds (Maruyama et a l, 2010). Very recently, 10 unique mutations in 15 individuals have been discovered in 
SQSTMl/p62  that are associated with ALS, which has led to the suggestion that p62 may be involved in ALS pathogenesis (Personal Communication: Fecto et 
al., 2011). In addition to the strictly ALS phenotypes, mutations in the MAPT gene are associated with a combined ALS and FTD phenotype (Curcio et a l, 2002). For a complete list of all known genetic linkages in ALS, please refer to 
Table 1.1 above.
In addition to mutations in genes leading to familial forms of ALS, other mutations have been associated with events that may lead to ALS or other ALS- like phenotypes. For example, the altered expression of Excitatory amino-acid transporter 2 [EAAT2] may affect surrounding mRNAs and RNA binding proteins, although its exact role remains to be determined (Strong, 2010). Spinal muscular atrophy has been associated with an abnormal copy number of 
SMN leading to its decreased expression (Corcia et a l, 2002; Veldink et a l, 2005). Finally, the gene that encodes the intermediate filament protein
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peripherin, which is known to form NCIs in ALS, can form multiple splice variants as a result of alternative splicing of PRPH (Robertson e ta l, 2003).
Biology and Pathobiology of ALS
Although the exact pathogenic mechanism of ALS has yet to be determined, several contributing factors have been identified. The classical pathology within motor neuron cell bodies includes the presence of intermediate filamentous NCIs. One type of intermediate filament isneurofilament [NF], which is composed of 3 subunits. The 3 subunits are named/for their molecular weight and include high molecular weight NF [NFH], intermediate molecular weight NF [NFM], and low molecular weight NF [NFL]. The presence of NF NCIs has been associated with suppression of steady state NFL mRNA levels (Bergeron et al., 1994; Menzies et al., 2002).
The contemporary thinking, however, is that ALS is a disease of altered RNA metabolism. The evidence supporting this includes: (1) RNA binding proteins have been shown to be abnormally expressed in ALS, but not in neuropathologically normal controls, (2) abnormal RNA binding protein expression is related to the suppression of NFL mRNA, and (3) mtSODl, TDP-43, FUS/TLS and RGNEF [see Chapters 2 and 3], all of which form NCIs in ALS, modulate NFL mRNA stability (Strong, 2010). In addition, some mutations with known associations to ALS occur in the genes encoding RNA binding proteins,
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which in turn affect RNA-mediated processes. Namely, these include mutations in SOD1, TARDBP, and FUS/TLS, which are detailed in Table 1.1.
Interestingly, the abnormal expression of some of the proteins thought to be involved in the pathogenesis of ALS can be targeted for protein degradation through the association with degradative markers. This is important because it is suggestive that protein degradation may be involved in the pathogenesis of ALS. Because ALS is known to be a disease associated with multiple proteins, and because this thesis utilizes various protein expression patterns to draw conclusions, what follows is a discussion of the biology and neuropathology ofthe proteins involved in this work. Since the first immunohistochemical/descriptions of neuropathology in ALS, work centered on the presence of NCls has been a general focus within the field (Strong et a l, 2005). For the purposes of this thesis, NCls are defined as aggregates or filamentous skein-like protein accumulations within affected anterior horn MNs.
TDP-43
TDP-43 is a 414 amino acid protein whose gene, found on chromosome lp36.2, contains 1 non-coding and 5 coding exons (Buratti and Baralle, 2001). It contains 2 RNA recognition motifs and a glycine-rich region on the C-terminus that allows it to bind DNA, RNA, and other proteins (Wang et al., 2004). Its role as a dual DNA/RNA binding protein is conducive to its wide array of functions in gene expression. TDP-43 acts to regulate pre-mRNA alternative splicing (Buratti and Baralle, 2001) as well as transcription, and increasing evidence
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points to its involvement in mRNA transport, stabilization, and degradation, as well as translation, and microRNA [miRNA] biogenesis (Buratti and Baralle, 2008; Warraich et al., 2010). As further evidence to its role in RNA metabolism, TDP-43 has been shown to be a component of RNA granules isolated from rat brain (Elvira et al., 2006). This suggests involvement in RNA trafficking, an important step of gene expression. TDP-43 has also been shown to act as a stabilizer of human NFL mRNA through a direct interaction to its 3' untranslated region [3’UTR] (Strong et a l, 2007). Due to the evidence that ALS is an RNA-mediated disorder and because TDP-43 has been shown to be functionally integrated in gene expression, much of the ALS field has targeted it as the pathological protein in ALS. Much of this speculation, however, is due to the cellular pathology of TDP-43.
The normal intraneuronal localization of TDP-43 is nuclear with minimal cytoplasmic presence in RNA granules. In ALS tissues, however, the expression of TDP-43 is upregulated approximately 1.5 fold (Mishra et al., 2007; Geser et 
al., 2008) and there is a transition from nuclear to cytoplasmic localization. Recent work has suggested that this nucleocytoplasmic redistribution is a reversible, normal response to injury (Moisse et al., 2009). TDP-43 has been shown to form NCls in ALS, but not in healthy controls. These inclusions have been shown to be ubiquitinated in ALS (Arai et a l, 2006; Neumann et al., 2006), suggesting that TDP-43-positive NCls are being targeted for degradation (Strong et al., 2007), although a lack of direct TDP-43-ubiquitin co-localization has been speculated (Sanelli et al., 2007). As discussed above, mutations in
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TARDBP have been found in both familial and sALS. Ubiquitinated, TDP-43- positive NCIs have been observed in cases of ALS that do not harbour a mutation in TARDBP. Of note is the aberrant phosphorylation of TDP-43 in these NCIs, which has been shown to associate with the pathogenesis of multiple neurodegenerative diseases, including ALS (Fujiwara e ta l, 2002).
FUS/TLS
Like TDP-43, FUS/TLS is a dual DNA/RNA binding protein that has multiple functions in gene expression. Due to its more recent discovery, less is known about the biological role of FUS/TLS; however, current studies suggest that it is found to associate with the heterogeneous ribonucleoprotein [hnRNP] complex involved in pre-mRNA splicing and the extra-nuclear transport of fully processed transcript (Iko et a l, 2004). In addition, FUS/TLS is associated with Drosha [a nuclear RNase III] in the microprocessor complex, suggesting that it likely has a role in miRNA processing (Gregory et a l, 2004). As mentioned above, FUS/TLS has multiple motifs that allow it to perform its functions. Given its role in RNA metabolism, the RRM was considered to be crucial for RNA targeting, but this was proven not to be the case by Zinszner and colleagues (Zinszner et a l, 1997). In fact, the zinc-finger motif has been shown to outperform the RRM with respect to RNA interaction (Iko et a l, 2004).
FUS/TLS is a ubiquitous protein and cellular localization is cell-type dependent (Yang et a l, 2010). The typical FUS/TLS expression pattern is similar to that of TDP-43: mainly nuclear, with lower levels seen throughout the
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cytosol (Andersson et al., 2008). Within the brain and spinal cord of ALS patients, however, FUS/TLS-positive NCls can be found that are also immunoreactive for TDP-43, ubiquitin, and p62. The same report, which presented convincing evidence for the importance of optimizing staining conditions via antigen retrieval and optimal antibody selection, presented FUS/TLS-positive inclusions in mtFUS/TLS-ALS cases (Deng e ta l, 2010).
Mutant SOD1
SOD1, as briefly mentioned above, is an enzyme whose sole function is thought to be the catalytic conversion of toxic superoxide free radicals to molecular oxygen [O2] and hydrogen peroxide [H2O2], which is further reduced to H2O by other enzymes. It is a ubiquitous protein, can be found in any cell in the human body and in any organism above bacteria, and accounts for 0.5-0.8% of the soluble protein in the human brain and spinal cord (Andersen, 2006). The pathological effect of mtSODl is not due to a loss of enzyme function, but rather due to a toxic gain-of-function. The toxic properties of SOD1 seem to be gained when Zn2+ is lost from the protein, seemingly enough of an assault to cause MN cell death (Estevez et al., 1999). Many mutations within SOD1 are known to affect the structural integrity of the protein, and as a result, Zn2+ is lost and SOD1 becomes toxic (Deng et al., 1993). Past studies characterizing the localization of SOD1 expression within MNs have shown abnormal aggregation within ALS 1 cases (Stieber et al., 2000). Mutant SOD1, but not wild type, has been shown to bind directly to the 3’UTR of NFL mRNA, which is necessary to
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induce mRNA destabilization (Ge et al., 2005). These findings support the hypothesis that ALS is a disease of altered RNA metabolism and are the grounds for the focus on mtSODl throughout this thesis as opposed to wild type SOD1.
RGNEF
RGNEF is a novel protein and the human homologue of the murine pl90RhoGEF (Volkening et al., 2010). In the mouse, pl90RhoGEF is a stability factor for NFL mRNA through its interaction adjacent the stop codon and extending into the 3’UTR (Canete-Soler et al., 2001). Additionally, pl90RhoGEF was shown to interact with NFL subunits that were not polymerized into filaments, an interaction that is associated with decreased NFL mRNA levels and subsequent NFL aggregation (Lin et al., 2005). Early studies on RGNEF have proven its in vitro interaction with NFL mRNA isolated from brain and spinal cord in ALS cases, but not in controls (Volkening et al., 2010). More recent work has connected ALS pathology via RGNEF to RhoA signaling cascades (Droppelmann, C e ta l, Submitted, 2011).
There is evidence of the formation of RGNEF-positive NCIs in ALS cases but not in neuropathologically normal controls. This manuscript has also provided evidence that aberrant RGNEF-positive NCIs can be targeted for degradation through the proteasome degradation pathway due to their co­localization with ubiquitin and p62 [see Chapter 3].
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High Molecular Weigh Neurofilament
Neurofilament is one of the major intermediate filaments of the cytoskeletal network of adult MNs. As mentioned, 3 subunits classified by their molecular weight [low, intermediate, high] make up the NF polymer. The presence of NFL is necessary for correct NF assembly and integrity, and stoichiometric ratios between NFL, NFM and NFH are variable (Sakaguchi et a l, 1993). In complex, these subunits polymerize into 10 nm structures and run the length of an axon. In mouse models in which the stoichiometric ratio between NFL, NFM, and NFH is disrupted, a motor neuronopathy withphosphorylated NFH [pNFH]-positive NCls develops [Julien, 1999; Beaulieu et
/
a l, 2000). Phosphorylated tails of NFM and NFH extend out from the NF complex; these phosphorylated tails interact with other filaments and axonal proteins, participating in cross-bridge formation and the regulation of interactions with other cytoskeletal elements. Phosphorylation of NF subunits is thought to expand axonal caliber as well as lateral spacing between NF subunits (Nixon etal., 1994).
As mentioned, one of the classic pathological hallmarks of ALS is the accumulation of intermediate filamentous NCIs (Strong et al., 2005). This can manifest itself in the aberrant aggregation of pNFH, which is associated with a down-regulation of steady-state levels of NFL mRNA (Bergeron et al., 1994; Wong et a l, 2000; Menzies et a l, 2002). The other NF-related classic pathological hallmark in ALS that is of relevance to this thesis is the presence of
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neuroaxonal enlargements. Smaller axonal enlargements (in the 6-20 urn range) are referred to as globules and are normal (Carpenter, 1968). Larger enlargements, however, referred to as neuroaxonal spheroids and defined as greater than or equal to 30 pm at their smallest diameter, are considered to be part of the pathology of ALS (Carpenter, 1968) and may have a role in the obstruction of axonal transport of various proteins (Strong et al., 2005).
Peripherin
Another neuronal intermediate filament protein, peripherin is a type III intermediate filament protein that is capable of self-assembling to form homopolymeric filamentous networks (Cui et a l, 1995). Much like the NF subunits, peripherin shares a similar secondary protein structure including an alpha helix, which is highly conserved across the different types of intermediate filaments (Xiao et al., 2006). After injury, peripherin expression is known to be upregulated in various neuronal types, including MNs (Troy et al., 1990; Wong and Oblinger, 1990). It has been reported that up-regulation of peripherin may be associated with neuronal regeneration (Troy e ta l, 1990; Wong and Oblinger, 1990). Paradoxically, transgenic mice over-expressing wild type mouse peripherin develop a motor neuronopathy characterized by the development of peripherin-positive NCIs (Beaulieu et a l, 1999). In mice, 3 alternative splice variants of peripherin are known [Per 56, Per 58, Per 61] (Robertson et a l, 2003). The function of these alternative splice variants is not known, however Per 56 appears normally expressed with Per 58 in vivo, whereas Per 61 does not
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appear to be involved in normal expression of the peripherin gene and actually has proved to be neurotoxic [Robertson et al., 2003]. This same study used isoform-specific antibodies to detect Per 61 within MNs of S0D1G37R transgenic mice, but never within MNs of healthy controls or peripherin transgenic mice. This suggests that alternative splicing of peripherin leads to splice variants that may be actively involved in the pathogenesis of ALS.
Like neurofilamentous inclusions, peripherin-positive NCIs may take the form of either neuroaxonal spheroids and/or somatic inclusions. In addition, peripherin-positive NCIs can take the form of Lewy body-like inclusions that are highly immunoreactive with ubiquitin antibodies [He and Hays, 2004). Interestingly, peripherin-positive inclusions are known to be a commonality between sALS and fALS and may represent a point of convergence with respect to disease pathogenesis [Xiao e ta i, 2006).
Ubiquitin
Ubiquitin is a highly conserved 76 amino acid protein that is ubiquitously expressed. It is an important protein in neurodegenerative diseases because of its association with the proteasome degradation pathway. The proteasome is a large protein complex found universally across eukaryotic cells. It contains proteases whose function is to degrade misfolded proteins into small 7 or 8 amino acid peptides, which are then further degraded to amino acids, which can then be used to synthesize new proteins [Ciechanover, 1994). The significance of this discovery was acknowledged in awarding the 2004
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Nobel Prize in Chemistry to Aaron Ciechanover, Avram Hershko, and Irwin Rose for their discovery of ubiquitin-mediated protein degradation. The role of ubiquitin in the process of proteasome-mediated degradation is to label proteins that are to be degraded by the cell with at least 4 ubiquitin molecules (Thrower et a l, 2000). This leads to the targeting of the protein for degradation by the proteasome (Haas and Rose, 1982; Haas etal., 1982).
The field of ALS changed in 1991 upon the discovery of ubiquitin- positive NCIs in the extra-motor cortices in patients with ALS (Okamoto et a l, 1991). This was a critical finding because of the known relationship between poly-ubiquitin labeling and protein degradation, and confirmed that unidentified proteins were likely involved in the pathogenesis of ALS. Shortly thereafter, the intermediate filament proteins associated with ALS were found to co-localize with ubiquitin-positive NCIs in Betz cells (Sasaki and Maruyama, 1991; Sasaki and Maruyama, 1992). There were, however, many more ubiquitin-positive NCIs, within the same and different cases, that were not immunoreactive for the intermediate filament proteins, and were not morphologically similar to intermediate filament-positive NCIs. Many of these unidentified, ubiquitin-positive NCIs were found to be immunoreactive with TDP-43 (Arai et a l, 2006; Neumann et a l, 2006), which was the discovery that began the research focus on TDP-43. Now, with the association of other RNA binding proteins, such as FUS/TLS (Deng et a l, 2010) and RGNEF [see Chapter 3], with ubiquitin-positive NCIs, and the knowledge that ubiquitin may be associated with the pathogenesis of ALS, ALS is increasingly being regarded as a
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disease of altered RNA metabolism. The pathological presence of ubiquitin- positive NCls is evidence for protein degradation via the proteasome complex, and is a crucial pathological marker of ALS.
Sequestosome 1 [p62]
P62 is a 62 kDa, 440 amino acid protein that is known to be expressed in many tissues (Ishii et a l, 1996; Rachubinski et a l, 1999]. P62 has a ubiquitin- binding associated C-terminal domain that has a high affinity for poly-ubiquitin chains (Vadlamudi and Shin, 1998]. It is known to act as a scaffold protein in that it can bind many signaling molecules, thus playing a role in linking poly- ubiquitination with various signaling events [Geetha and Wooten, 2002]. The link between neurodegeneration and p62 became evident with the finding that elevated levels of neuronal and glial p62 can be found in human tauopathies and synucleinopathies (Kuusisto et al., 2001]. Namely, elevated intraneuronal expression of p62 has been found in Alzheimer's disease, Pick's disease, frontotemporal dementia, Parkinson’s disease, dementia with Lewy body disease, and multiple system atrophy, in addition to ALS.
P62-positive NCIs have been found in ALS cases, but not in controls. Specifically, p62-positive NCls have been reported in skein-like inclusions, Lewy body-like inclusions, and basophilic inclusions (Mizuno et a l, 2006] and are known to co-localize with ubiquitin. These findings suggest that p62 is important in the protein-proteasome degradation pathway.
24
Optineurin
Optineurin is a 66 kDa, 574 amino acid protein that has traditionally been associated with primary open-angle glaucoma [POAG] (Rezaie e ta l, 2002). There have been many reports of mutations in OPTN associated with POAG although the mechanisms through which these mutations may lead to POAG are currently unknown. Aberrant optineurin expression causes motor neurons to utilize either the TNF-alpha or Fas-ligand pathway to undergo apoptosis, inflammation, or vasoconstriction (Sarfarazi and Rezaie, 2003). In a Japanese population, 3 distinct mutations in OPTN have been associated with ALS: 1 missense autosomal dominant, 1 nonsense autosomal recessive, and 1 deletion leading to an autosomal recessive mutation (Maruyama et al., 2010). Mechanistically, it is likely that the recessive mutations lead to a loss-of- function, while the dominant mutation is association with a gain-of-function.
Optineurin immunostaining has revealed optineurin-positive NCIs in ALS cases, but not in healthy controls. More specifically, NCIs were optineurin- positive in some sALS and fALS cases without any known mutations. In addition, neuritic staining was evident and seemed to be more intense in cases of sALS. Some of these inclusions were ubiquitin and TDP-43-positive as well, suggesting a unifying role for optineurin in disease pathogenesis. Interestingly, optineurin-positive NCIs were also found in cases of ALS 1 (Maruyama et a l, 2010). More recent work, however, has suggested that optineurin-positive NCIs are in fact present in a minority of cases and that optineurin does not likely play
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a role in the pathogenesis of ALS or in any other neurodegenerative disease (Hortobagyi et a l, 2011; Sugihara et a l, 2011). This conclusion is based upon large studies that looked for OPTN mutations in non-Japanese populations as well as immunohistochemical observations.
RNA Metabolism and ALS
One of the key aspects of the Central Dogma of Molecular Biology is RNA metabolism [Crick, 1970). As briefly discussed above, there is considerable evidence suggesting that ALS is a disease of altered RNA metabolism. To summarize, the evidence supporting this is:
1. RNA binding proteins have been shown to be abnormally expressed in ALS;2. Mutations in genes encoding these RNA binding proteins affect RNA mediated processes such as splicing, transcription, translation, transport, and degradation;3. Abnormal RNA binding protein expression is related to the suppression of NFL mRNA; and,4. The 4 RNA binding proteins discussed thus far, mtSODl, TDP-43, FUS/TLS, and RGNEF, form NCIs in ALS and are all known to modulateNFL mRNA stability.
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As the knowledge base of information regarding RNA metabolism grows, it is increasingly regarded as a very dynamic process. It is now known that protein expression is somatotopic in that protein synthesis occurs at variable sites within the cell, responding to cellular protein needs (Strong, 2010). For somatotopic expression to successfully occur, it is necessary for mRNA to be shipped throughout the cell for translation at optimal sites. This occurs via RNP complexes, which can be identified as RNA granules. In general, RNP complexes consist of multiple building blocks: ribosomal subunits, translation factors, decay enzymes, helicases, scaffold proteins, molecular motors, and RNA binding proteins, all of which control the complex' localization, stability and translation of RNA contents (Anderson and Kedersha, 2006). RNP granules exist within a cell in 3 main forms: transport granules, stress granules, and cytoplasmic processing bodies [P-bodies]. Due to the fact that RGNEF has been proven to be an RNA binding protein and given that this thesis will be characterizing RGNEF expression for the first time, what follows is a discussion of several additional relevant proteins.
Staufen [Transport Granules]
Characteristic of transport granules, Staufen is present within RNA granules when the mRNA is translationally silent and being shipped to the site of protein synthesis. It is possible for these granules, which contain all of the machinery necessary for RNA translation, to be shipped to distal axonal sites. Transport granules are a normal part of RNA metabolism and can be found in
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damaged and healthy cells alike. Staufen is an accepted marker for transport granules, and is used as such within this thesis.
TIA-1 [Stress Granules]
Used as a marker for stress granules, TIA-1 is present within RNP complexes whose core constituents are stalled 48S pre-initiation complexes (Kedersha et a l, 2002; Kimball et al., 2003). Pre-initiation complexes are evidence that the initial steps of translation have occurred, but due to some environmental stress, translation was not able to move forward. The induction of stress granules is rapid following the environmental stress and usually occurs within 15-30 minutes (Anderson and Kedersha, 2006). The transformation into a translationally silent granule then occurs via the phosphorylation of a translation initiation factor by a family of stress-activated kinases, and results in polysome disassembly (Anderson and Kedersha, 2006). Although many proteins exist within stress granules, TIA-1 is accepted as the preferred marker for stress granules, and is used as such within this thesis.
XRN-1 [P-bodies)
Found in P-bodies, the 5'-3' mammalian exonuclease XRN-1 is one component of a complex containing decay machinery for each step of the mRNA decay process. Although generally recognized as a state from which mRNA will be degraded and its components used for other purposes, P-bodies share many features in common with stress granules, including a common origin (Strong, 2010), and they actually exist interchangeably with one another (Barbee et a l,
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2006; Anderson and Kedersha, 2008). XRN-1 is the accepted marker for P- bodies, and as such, is used in this thesis.
L26 [Polysomes]
Polysomes are clusters of ribosomes that bind to molecules of mRNA and work to synthesize protein from the transcript at multiple locations. In a micrograph, polysomes can be visible as coarse granular structures throughout the cell that are the sites of protein synthesis. The most prominent component of the large ribosomal 60S subunit is rRNA, which is held together by proteins, thus allowing it to perform its catalytic function. L26 is a ribosomal protein of the 60S subunit. It has been shown to help bind the 5’UTR of p53 mRNA and to control p53 translation (Takagi et a i, 2005). Thus, L26 is the marker of polysomes and translationally active granules used throughout this thesis.
As suggested by the number of proteins discussed thus far, RNA metabolism is a complex, dynamic process with many possibilities for aberrancies to occur. For a schematic of the process of RNA metabolism and how these proteins contribute, please see Figure 1.1: RNA Metabolism (Strong, 2010).
Glutamate Excitotoxicity
As briefly mentioned, the only pharmaceutical currently used to combat ALS, riluzole works by inhibiting pre-synaptic glutamate release
Figure 1.1: RNA Metabolism.
Due to the important role for RNA metabolism in ALS and throughout this thesis, this schematic outlines the dynamic complexity of the process and how various relevant proteins discussed thus far fit into it.
1. TDP-43 has numerous roles, and is known to be involved in transcription, mRNA splicing, miRNA biogenesis and nucleocytoplasmic shuttling. Consistent with its role in transport, TDP-43 has been found in RNP complexes.2. FUS/TLS is known to be involved in transcription, mRNA splicing and miRNA biogenesis.3. RGNEF is a signaling molecule, but is known to be an active protein in RNA metabolism due to its presence in RNA granules [see Chapter 3].4. Mutant SOD1 is known to be involved in neuronal toxicity due to a gain- of-function mechanism. As discussed, this can result in neuronal death via an RNA degradative mechanism.5. L26 is a protein found in the large ribosomal subunit, a primary component of polysomes, and an accepted marker of translational activity.
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(Zinman and Cudkowicz, 2011). Other promising compounds have been tested in clinical trials, although all trials have been negative. The commonality amongst almost all of these compounds that have made it to clinical trials is their targeting of glutamate pathways. L-Glutamate is the most abundant amino acid in the mammalian central nervous system and functions as an excitatory neurotransmitter (McEntee and Crook, 1993). MN death has been induced by glutamate in vitro and is mediated by the 2 most characterized glutamate receptors: NMDA receptors and AMPA receptors (Van Den Bosch and Robberecht, 2000). In ALS, a cytotoxic effect due to a massive influx of calcium has been shown following excessive stimulation of these receptors (Shaw, 2005). Increased glutamatergic stimulation can lead to excitotoxic effects, which come as a result of an increase in synaptic cleft glutamate concentration.
Oxidative Stress
The type of cellular injury that is more applicable to this thesis is oxidative stress. Clearly involved in ALS pathogenesis, researchers are unsure whether oxidative stress is a cause of disease pathogenesis or merely an effect of some unknown upstream event. The main cause of oxidative stress is an accumulation of reactive oxygen species [ROS], which are believed to be associated with aging (Beal, 2002; Lenaz et a l, 2002; Genova et al., 2004). As described above, SOD1 is a key regulator of ROS accumulation, and has been implicated in ALS pathogenesis. Although some mutations in SOD1, such as A4V
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and G85R, lead to a decrease in enzymatic activity, other mutations, such as G37R (Borchelt et a l, 1994) and G93A (Yim et a l, 1996), allow S0D1 to retain its full activity. Additionally, S0D1 knockout mice do not develop an ALS phenotype (Reaume et a l, 1996). Taken together, these data have led to the currently accepted beliefs that a lack of ROS removal is not sufficient to be cytotoxic, and that a loss of SOD1 activity is not sufficient to cause ALS.
Glial Involvement in ALS
One aspect of innate immunity is inflammation, which is a normal cellular response to environmental injury (Moisse and Strong, 2006). Because antigens do not stimulate it, the innate immune response is generally executed by phagocytes and is non-specific. One type of phagocyte is the macrophage, and the resident macrophage of the central nervous system [CNS] is the microglia. Another type of glial cell that is known to be involved in ALS is the astrocyte. Due to the relationship between cellular injury, inflammation, and ALS, and the subsequent involvement of microglia and astrocytes, what follows is a discussion of glial involvement in ALS. This discussion is pertinent to this thesis because RGNEF expression has never been characterized, and one aspect of its characterization includes a potential involvement in glial cells [seeChapter 3].
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Microglia
Microglia act as support cells for neurons within the CNS through the production of anti-inflammatory cytokines, neurotrophins, and growth factors. They can also phagocytose unneeded cellular debris following injury or disease. Some studies have challenged these findings with the identification of the release of pro-inflammatory factors that show microglia enhancing neuronal injury (Banati et a l, 1993; Aldskogius and Kozlova, 1998). When MN injury occurs, a morphological transition of microglia follows that is known as "priming” (Perry et al., 2003) and can be a result of neurodegeneration (Cunningham et a l, 2005), stress (Johnson et a l, 2002), or aging (Godbout et a l, 2005). Primed microglia have thickened cell bodies and processes, with a more intense local surveillance.
In ALS, considerable evidence exists for the proliferation and activation of microglia (Lampson et a l, 1990; Troost et a l, 1990; McGeer et a l, 1991; Kawamata et a l, 1992; Troost et a l, 1993; Wilson et al., 2001; Henkel et a l, 2004; Solomon et a l, 2006). Importantly for this thesis, these observations have been made in the anterior horn of the spinal cord (Kawamata e ta l, 1992), which is the location on which the studies in this thesis have focused. The microglial marker used in this thesis is ionized calcium binding adaptor molecule 1 [IBA-1]. IBA-1 has been associated with an inflammatory response, and has been shown to be up-regulated in microglia as a response to injury and in ALS tissues (Moisse e ta l, 2009).
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Astrocytes
Also part of the neuroinflammatory response, the primary role of astrocytes in the CNS is to mediate extracellular glutamate levels, thus mediating the potential for excitotoxic neuronal degeneration. Outnumbering neurons approximately 10 to 1, they also provide trophic support for surrounding neurons (Sofroniew and Vinters, 2010]. Astrocytes are able to participate directly in inflammatory reactions. Injured MNs have been found to secrete fibroblast growth factor-1 [FGF-1], which is known to lead to an accumulation of FGF-1 receptors in astrocytic nuclei (Cassina e ta l, 2005). This accumulation stimulates astrocytic nerve growth factor expression, which was previously linked to MN apoptosis via a p75-dependent mechanism (Cassina et 
a l, 2002; Pehar et a l, 2002).
Astrocytes are activated in ALS tissue as well as in mtSODl human transgenic mice (Engelhardt and Appel, 1990; Kushner et a l, 1991; Kawamata 
etal., 1992; Engelhardt e ta l, 1993; Nagy e ta l, 1994; Schiffer e ta l, 1996; Hall et 
a l, 1998; Alexianu et a l, 2001). As with microglia, astrocytic activation is characterized by a larger cell body and thicker astrocytic processes. Characteristic of astrocyte activation is an up-regulation of the intermediate filament glial fibrillary acidic protein [GFAP] (Philips and Robberecht, 2011), which is the astrocytic marker used within this thesis. This increased astrocytic expression causes a down-regulation of the glutamate transporter EAAT2, which causes a decreased glutamate transport and a possible active release of
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glutamate [Lin et a l, 1998). This leaves MNs more susceptible to excitotoxic damage.
Motor Neuronal Death in ALS
One of the ongoing debates in the field of ALS research is the mechanism by which MN cell death occurs. One of the reasons for this debate is the difficulty associated with catching a MN in the dying process in human tissue because it is seen just at a "snap-shot" in time. Three main types of cell deathhave been proposed: apoptosis, necrosis, and autophagy. What follows is a brief
/discussion of each mechanism and its potential role in MN death in ALS.
Apoptosis is a tightly regulated, programmed, energy-dependent process that is specifically designed to switch off unneeded or damaged cells and eliminate them. This occurs through the formation of small cellular fragments called apoptotic bodies that surrounding cells such as macrophages can engulf and degrade. There are several characteristic morphological changes observed of the cell undergoing apoptosis. The first of these is the shrinkage of the cell and the formation of blebs on the cell membrane. At the same time, the nucleus becomes pyknotic before karyorrhexis, marked by a fragmented nucleus, occurs, and apoptotic bodies appear from the fragmented cell. At a molecular level, pro-apoptotic markers can be present (Yoshiyama et a l, 1994; Mu et a l, 1996; Ekegren et a l, 1999; Martin, 1999; Gonzalez de Aguilar et a l, 2000; Martin, 2000; Guegan et a l, 2002), and anti-apoptotic factors such as the
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proteins of the Bcl-2 family are down-regulated (Martin, 1999; Vukosavic et a l, 1999). These finding have been replicated in human tissue from ALS patients as well as in mouse models of ALS.
Necrosis is cellular death followed by inflammation that is caused by some environmental stress. In contrast to apoptosis, necrosis is not programmed, and is therefore not planned for by the cell. Past studies have revealed necrotic cell death in ALS due to excitotoxic cellular injury (Glazner et 
al., 2000), and DNA fragmentation, which has been shown to occur in apoptosis as well as necrosis.
Autophagy is a mechanism for eukaryotic cells to degrade intracellular components and its altered regulation can contribute to neurodegeneration. In contrast to ubiquitin-proteasome protein degradation that was discussed earlier and tends to degrade short-lived misfolded proteins (Ciechanover, 2006), autophagy is the lysosomal degradation of organelles and long-lived cytoplasmic proteins (Marino and Lopez-Otin, 2004). Both the inhibition (Hara 
et a l, 2006; Komatsu et a l, 2006) and excessive activation (Tsujimoto and Shimizu, 2005) of autophagy can lead to cell death, the former provoking neurodegeneration and the latter causing auto-digestion. Thus, the effects of autophagy on the ALS MN depend on its temporal, spatial, and degree of activation (Pasquali et a l, 2009). Microscopic examination of post-mortem human tissue has revealed phenotypic evidence of autophagic MN death (Przedborski, 2004). Further, autophagy has been implicated in in vitro models
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of excitotoxicity-induced MN death [Matyja et a l, 2005). In that study, Matyja and colleagues demonstrated a different mode of cell death in excitotoxic MNs, and suggested a cell death continuum including apoptotic-necrotic and apoptotic-autophagic mechanisms. Motor neurons of m tSODlG93A mice have been shown to contain increased numbers of autophagosomes compared to wild-type mice (Morimoto et al., 2007), suggesting that autophagy is involved in cell death in transgenic mouse models of ALS. Taken together, multiple studies have implicated autophagy as a mechanism involved in cell death in ALS.
Evidence exists in support of each of the mechanisms discussed above. Molecular and morphological findings do not fully support one mechanism in all cells, so a definitive mechanism of cell death has yet to be agreed upon.
Rationale and Hypothesis
It has been demonstrated that ALS is a disease of altered RNA metabolism, and that many proteins are involved in regulating the RNA metabolic process, including the novel NFL mRNA binding protein, RGNEF. In addition to the RNA binding proteins that regulate RNA metabolism, several other proteins have been introduced, all of which have been suggested to play unique roles in the pathogenesis of ALS. Further, several variants of ALS have been introduced. 1 have sought to examine the relationship between the immunohistochemical expression of various ALS-associated proteins and, for the first time, characterize RGNEF pathology, across multiple variants of ALS. In
38
doing so, I have tested the hypothesis that all variants o f  A L S  are  
pathologically distinct and can be differentiated by spinal cord pathology  
using a panel o f  contem porary ALS-associated markers.
In Chapter 2, I will demonstrate that ALS is indeed characterized by aberrant RNA binding protein expression, and I will show that mtSODl-ALS is a pathologically distinct variant of ALS.
In Chapter 3 ,1 will show that RGNEF can be aberrantly expressed in ALS tissues, but not in neuropathologically normal controls, and that it is likely involved in the pathogenesis of ALS. I will also show that RGNEF is actively involved in the RNA metabolic pathway and that it does not seem to be involved in neuroinflammation. Finally, I will provide evidence that further supports the hypothesis that ALS is a disease of altered RNA metabolism.
In Chapter 4 ,1 will summarize my findings and discuss the implicationsof this work as well as future directions.
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Abstract
Recent studies have associated various genetic mutations with amyotrophic lateral sclerosis [ALS], including mutations in the genes encoding superoxide dismutase 1 [SOD1], fused in sarcoma/translocated in liposarcoma [FUS/TLS], TAR DNA-binding protein of 43 kDa [TDP-43], and optineurin. The contribution of these mutations with respect to ALS motor neuron pathology remains to be elucidated. Our aim in this study was to analyze spinal anterior horn cells [AHCs] in patients with identified mutations in S0D1 [n=5], FUS/TLS [n=2], and TARDBP [n=2], and compare this with protein expression, at the light microscopy level, in cases of sporadic ALS [sALS] [n=6] and familial ALS [fALS] [n=5] without any known mutations. We performed 3,3’-Diaminobenzidine immunohistochemistry [1HC] using a panel of contemporary ALS-associated markers, which included antibodies against TDP-43, FUS/TLS, S0D1, ubiquitin, sequestosome 1 [p62], optineurin, phosphorylated high molecular weight neurofilament [pNFH], peripherin, and a novel antibody against Rho-guanine nucleotide exchange factor [RGNEF]. With the exception of mutant [mt] SOD1- ALS cases, we observed neuronal cytoplasmic inclusions [NCIs] in all variants of ALS when evaluated for TDP-43, FUS/TLS, RGNEF, peripherin, and pNFH. SODl-positive NCIs were only observed in cases of mtSODl-ALS. Common to all variants of ALS, regardless of pathophysiology, were p62-positive NCIs. Our data suggests that mtSODl-ALS is a pathologically unique variant of ALS and prudent IHC-based pathological analysis of AHCs can aid clinicians in identifying novel families affected by Type 1 fALS.
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Introduction
Amyotrophic lateral sclerosis [ALS] is a fatal neurodegenerativo disease characterized by the progressive loss of upper and lower motor neurons [MNs] in the brain and spinal cord (Logroscino et a l, 2008]. Death from ALS usually comes 3 to 5 years after symptom onset due to respiratory failure. Although the cause(s) of ALS have not yet been determined, several mechanisms and/or cellular processes have been identified that likely play a role in disease pathogenesis. These include toxic gain-of-function mutations in the gene encoding superoxide dismutase 1 [SOD1] (Rosen et a l, 1993), aberrant neuronal cytoplasmic inclusions [NCIs] of TAR DNA binding protein of 43 kDa [TDP-43] (Arai et a l, 2006; Neumann et a l, 2006), the subsequent identification of mutations in the TARDBP gene in individuals with ALS (Kabashi et a l, 2008; Kuhnlein et a l, 2008; Rutherford et a l, 2008; Sreedharan et a l, 2008; Van Deerlin e ta l, 2008; Corrado etal., 2009; Daoud e ta l, 2009; Del Bo e ta l, 2009), abnormal inflammatory processes (Moisse and Strong, 2006), and the formation of insoluble NCIs (Strong et a l, 2005). It is likely that the pathogenesis of ALS is multi-factorial and all of these processes play a role.




Approximately 10% of ALS cases occur in a family with a known history of the disease and are thus identified as familial ALS [fALS]. Twenty percent of fALS cases have been found to be associated with mutations in the SOD1 gene (Rosen et al., 1993] and are thought to cause ALS through a toxic gain-of- function mechanism as opposed to a loss of function of the enzyme (Shaw, 2005). To date, there are 153 known mutations in the SOD1 gene that have been associated with ALS (Felbecker et al., 2010). The majority of these mutations are clustered around the edges of the protein's p barrel, within the dimer interface, or near one of the zinc-binding superoxide dismutase pockets(Beckman et al., 2001). Many of these mutations are known to affect
/interactions that are critical to the structural integrity of SODl's p barrel (Deng 
et al., 1993). The gain-of-function that causes SOD1 toxicity is achieved when Zn2+ is lost from SOD1, which is sufficient to cause MN cell death (Estevez et al., 1999). In addition, mutant SOD1 [mtSODl] has been shown to bind with the 3’ untranslated region of low molecular weight neurofilament [NFL] mRNA and act as a destabilizer (Ge et a l, 2005). Similarly, vascular endothelial growth factor mRNA is significantly down-regulated in the spinal cords of S0D1G93A mice (Lu et al., 2007). In the case of the S0D1G93A mouse, mRNA destabilization leads to an increase in the rate of neurodegeneration leading to ALS. Due to the fact that SOD1 exhibits increased RNA binding properties in its mutant form, we have classified it as an RNA binding protein for the purposes of this study.
Past studies characterizing the intraneuronal expression of SOD1 have shown abnormal aggregation within cases of ALS 1 (Stieber et al., 2000). We
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are unaware of any studies that have reported SODl-positive NCIs in any other variant of ALS.
TDP-43
TDP-43 is a dual DNA/RNA binding protein that functions in alternative splicing of mRNA as well as other processes related to protein expression (Buratti and Baralle, 2008). In healthy MNs, TDP-43 expression is typically nuclear with minimal cytoplasmic presence in RNA granules. TDP-43 was discovered to be abnormally expressed in ALS when ubiquitinated TDP-43- positive NCIs were observed (Arai e ta i, 2006; Neumann e ta l, 2006). Since that time, much work has centered on identifying mutations in the TARDBP gene, and since 2008, many TARDBP mutations have been found [Kabashi et al., 2008; Kuhnlein et a l, 2008; Rutherford et al., 2008; Sreedharan et a l, 2008; Van Deerlin et a l, 2008; Corrado et a l, 2009; Daoud et a l, 2009; Del Bo et a l, 2009). There are currently 30 distinct mutations that have been associated with ALS in 22 unrelated families and in 29 sporadic cases of ALS (Lagier-Tourenne and Cleveland, 2009; Perry et a l, 2010). The majority of TARDBP mutations are missense mutations that can be mapped to the glycine-rich, C-terminus of the protein and affect protein-protein interactions.
FUS/TLS
FUS/TLS is also a dual DNA/RNA binding protein that is typically expressed in the nucleus in healthy MNs and functions in transcription, RNA splicing, and transport (Kwiatkowski et a l, 2009; Vance et a l, 2009). The
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FUS/TLS protein is a 526 amino acid protein encoded for by 15 exons. It is characterized by distinct motifs including: an N-terminal serine-tyrosine- glutamine-glycine-rich [QGSY] region, a glycine-rich region, an RNA-recognition motif, multiple RGG repeats involved in RNA binding, a C-terminus zinc finger, and a highly conserved extreme C-terminal region (Lagier-Tourenne and Cleveland, 2009). In sALS and non-mtSODl fALS, FUS/TLS expression has been identified to be in the form of insoluble NCIs [Deng et a l, 2010). Recently, mutant forms of FUS/TLS have been described that are associated with fALS (Kwiatkowski et al., 2009; Vance et al., 2009). The majority of ALS-associated mutations are missense mutations and seem to cluster in the extreme C- terminus [aa514-525) [Perry et al, 2010). The only 2 identified mutations in 
FUS/TLS that are not missense mutations are in the C-terminus and involve the insertion or deletion of 2 glycines (Lagier-Tourenne and Cleveland, 2009).
RGNEF
RGNEF is a novel protein that is the human homologue of the murine pl90RhoGEF. It has been shown to regulate the stability of human NFL mRNA. Interestingly, this is a direct in vitro interaction that appears to occur in lysates from ALS tissues, but not in controls (Volkening et al., 2010). Recent data suggests an abnormal formation of NCIs that can be ubiquitin and p62-positive in ALS, but not in neuropathologically normal controls [see Chapter 3]. This suggests a role for RGNEF in the pathogenesis of ALS.
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Ubiquitin
Ubiquitin is a common marker of protein degradation through the ubiquitin-proteasome degradation pathway. Schiffer, D. et al. observed many clinically aggressive cases of ALS with a high percentage of ubiquitin-positive NCIs (Schiffer et al., 1991). Further, ubiquitin-positive NCIs are found across many variants of ALS, suggesting that protein ubiquitination is an early-stage event in the pathogenesis of ALS.
Sequestosome 1 [p62]




Recently, optineurin, a protein traditionally associated with primary open-angle glaucoma (Rezaie et a l, 2002] was discovered to be associated with ALS in 4 distinct Japanese families (Maruyama et a l, 2010). Three unique mutations were found, all of which cause the protein to lose its ability to inhibit the activation of nuclear factor kappa B (NF-k B). In addition to the pathophysiological effects caused by the mutations, optineurin-positive NCIs were found in these cases. Immunohistochemical staining reported by Maruyama et al. revealed optineurin-positive hyaline inclusions and NCIs that were also immunoreactive to antibodies against TDP-43 and ubiquitin in cases of sALS (Maruyama et a l, 2010]. More recent studies have suggested that optineurin is not likely a pathogenic commonality amongst all variants of ALS (Hortobagyi et a l, 2011).
High Molecular Weight Neurofilament [NFH]
High-molecular weight neurofilament [NFH] is 1 of 3 neurofilament [NF] subunits comprising the NF family of intermediate filaments. In the NF complex, the C-terminal tail of NFH is highly phosphorylated, promoting polymerization between NF subunits (Strong, 1999). The antibody used to detect NFH is specific to this phosphorylated form of NFH [pNFH]. NFs are major contributors to the neuronal cytoskeleton. Intraneuronal aggregates of NF proteins have been observed in ALS (Strong et a l, 2005). In addition,
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neuroaxonal spheroids, the largest of which have been suggested to be pathological in ALS (Carpenter, 1968), are pNFH-immunoreactive.
Peripherin
Peripherin, a type III intermediate filament protein, has been shown to abnormally aggregate in the cytosol of anterior horn cells [AHCs] (Migheli et al., 1993). Additionally, inclusions may form within the axon, leading to the presence of neuroaxonal spheroids. Traditionally, these intraneuronal aggregates have been seen as a pathological hallmark in ALS, which is why the expression of peripherin was analyzed in this study.
Clinical Link and Experimental Aims
The clinical diagnosis of ALS is based on a set of international criteria published in 1994 by the World Federation of Neurology (Brooks, 1994). Even a case that has been diagnosed as clinically "definite” for ALS can have a small incidence of misdiagnosis and thus requires pathological examination for absolute certainty (Ross et a l, 1998). The brainstem and spinal motor nuclei are examined for loss of lower MNs, and the corticospinal tracts and motor cortex are examined for loss of upper MNs. Some common pathological features that help to confirm the diagnosis are TDP-43-positive and ubiquitin-positive NCls. To date, no studies have been completed which discuss the linkage 
of unique intraneuronal ALS-associated protein expression patterns to
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specific variants of ALS. This study aimed to, first, determine if a link exists between intraneuronal pathology of ALS-associated proteins in AHCs and the variant of ALS, and, second, to determine the most robust and reliable markers of ALS pathogenesis that may be of use to neuropathologists in the pathological diagnosis of specific disease variants while providing genetic information without the need for gene sequencing.
Materials and Experimental Procedures
Genotvping and Case Selection
/  : ■ ; • -  i ;,We performed genotypic analyses on 137 cases of ALS from tissue archives at the London Health Sciences Center. The sequencing was performed at the Mayo Clinic College of Medicine in Jacksonville, FL. Sequencing revealed several cases harbouring genetic mutations known to associate with ALS in cases with previously unidentified mutations. For specific genetic findings, please refer to Table 2.1a.
Following this, we selected a panel of 20 ALS cases and 4 neurologically normal controls [Table 2.1b]. Of the 20 cases of ALS in our panel, 5 variants of ALS were represented: 5 cases of mtSODl-ALS [A4T (n=2), 1113T (n=2), D76Y], 2 cases mtTDP-43-ALS [C774G, *81-84 delCATA], 2 cases of mtFUS/TLS-ALS [R521C, 3’UTR*41G>A], 5 cases of fALS without any identified mutations, and 6 cases of sALS without any identified mutations [Table 2.1a].
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T y p e V a r i a n t S p e c i f i c  M u t a t i o n
H e a lt h y  C o n t r o l N / A N o  M u t a t io n  (n = 4 )
m t S O D l - A L S S 0 D 1 A4T ( n = 2 )
F a m ilia l  A L S
m t T D P - 4 3 - A L S
TDP-43C774G (n = l )
T D P - 4 3 81'84delCATA ( n = l )
m t F U S / T L S - A L S
FUS/TLS3'UTR*41G>A(;n = 13
F U S / T L S R521C ( n = l )
f A L S  -  n o  k n o w n  m u ta t io n s U n k n o w n  (n = 5 )
S p o r a d i c  A L S
m t S O D l - A L S
SOD1H13T (n = 2 )  
SOD1D76Y (n = l )
s A L S  -  n o  k n o w n  m u ta t io n s U n k n o w n  ( n = 6 )
Table 2.1a: Genetic details of the cases used in this study
Control Age Sex Cause of Death1 67 M Respiratory Failure (COPD)2 71 M Cardiac Arrest3 61 M Cardiac Arrest4 61 M Renal Failure
Table 2.1b: Information for control cases used in this study
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Immunohistochemistry was then performed in triplicate for each case using each antibody. Staining was performed on 3 different cases of neuropathologically normal control tissue in order to determine a normal protein expression pattern.
Antibodies
A goat polyclonal antibody against RGNEF was produced by 21st Century Biochemicals [260 Cedar Hill Street, Marlboro, MA, USA 01752] using the immunogenic peptide sequence 1567-INEALVQMSFNTFNKLNPSV-1586. All other antibodies used in this study were obtained commercially and immunoreactivity was optimized with antigen retrieval techniques and titres 
[Table 2.2].
Immunohistochemistry
Six-micrometer sections of formalin-fixed, paraffin-embedded spinal cord tissue were warmed at 63°C for 30 minutes and rehydrated through an ethanol series to lxPBS with 5-minute washes [xylenes, 1:1 xylenes:ethanol, 100% ethanol, 95% ethanol, 75% ethanol, 50% ethanol, lxPBS]. Following rehydration, antigen retrieval was performed as specified in Table 2.2 using a 2100 Retriever chamber [Pick Cell Laboratories, Lelystad, Netherlands]. Sections were washed 3 times for 5 minutes each using lxPBS and then treated for 5 minutes at room temperature with 3% H2O2 to block endogenous peroxidase activity. After 3 additional 5-minute washes with lxPBS, the sections were blocked for 60 minutes in 5% bovine serum albumin [Roche
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1:500 Proteintech [Cat # 10782-2-AP] Biotinylated Rabbit IgG [Vector, Cat # 
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1:500 Millipore [Cat # Abl530] Biotinylated Rabbit IgG [Vector, Cat # 
PK-61011
Tris-EDTA [0.05% 
Tween 20], pH 7.4
Table 2.2: Details of use for each antibody in this study
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Diagnostics, Mannheim, Germany] in water. Following blocking, the sections were incubated with antibodies against TDP-43, FUS/TLS, RGNEF, S0D1, ubiquitin, p62, optineurin, phosphorylated NFH [pNFH] or peripherin for 20 hours at 4°C. The sections were then washed 3 times for 5 minutes each in lxPBS and then incubated with the appropriate biotinylated secondary antibody for 60 minutes at room temperature [Vectastain Elite ABC Kit, Vector Laboratories, Burlingame, CA] [Table 2.2] at a titre of 1:500. Following 3 additional washes of 5 minutes each in lxPBS, the tissues were incubated with the avidin/biotin enzyme complex solution [Vectastain kits], washed in lxPBS 3 times for 5 minutes each and treated with 3,3’-diaminobenzidine [Sigma- Aldrich Canada, Oakville, ON]. Nuclear counterstaining was performed using Modified Harris Formula Haematoxylin [Ricca Chemical Company, Arlington, TX]. Sections were dried, mounted with Cytoseal 60 mounting medium [Richard-Allan Scientific, Kalamazoo, Ml], observed using a BX45 light microscope [Olympus, Markham, ON], and photographed with a Q Color 3 camera [Olympus, Markham, ON].
Protein Expression Analysis
Given the nature of our study, we evaluated protein expression qualitatively. Qualitative observations were made for all proteins and involved noting the presence or absence of protein-specific NCIs. Based on the literature, we defined NCIs as skeins and/or aggregates, which are hypothesized to be insoluble and are thus considered to be involved in the pathogenesis of ALS.
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Pathological neuroaxonal spheroids were described as greater than 30 pm at their smallest diameter.
Semi-quantitative observations were made for all non-RNA binding proteins. For expression patterns evaluated in a semi-quantitative manner, a score of + denotes the presence of less than 10 pathological inclusions per spinal cord section [both anterior horns], ++ denotes the presence of 10 or more pathological inclusions per spinal cord section, and -  denotes the absence of pathological inclusions.
A quantitative analysis was only made on tissues examined for TDP-43 immunoreactivity. All AHCs with evidence of a nucleolus were included in the quantification. Each AHC was analyzed twice: once noting the presence or absence of nuclear staining, and once noting the presence or absence of cytoplasmic staining. The percentage of counted cells that showed a nuclear expression pattern and the percentage of counted cells that presented with a cytoplasmic expression pattern were calculated for each case. The cases were then grouped by variant of ALS, and the mean nuclear and cytoplasmic expression levels were calculated using these figures. Based on past studies that highlighted the importance of the phenomenon, the degree of TDP-43 nucleocytosplasmic redistribution was calculated for each variant of ALS (Moisse etal., 2009).
All tissues across the panel of antibodies were analyzed in a blinded manner. One individual that was observing slides independently for all proteins
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examined further confirmed the methods used for the original analysis. A clear consensus was reached for every slide that was examined.
Statistical Analysis
A one-way ANOVA was performed with a Tukey-Kramer multiple comparisons post-hoc test in order to determine the significance of the nucleocytoplasmic redistribution of TDP-43 observed between all variants of ALS.
Results
TDP-43
In spinal cord tissues examined for TDP-43 expression, 198 AHCs were included from 3 neuropathologically normal control cases [Figure 2.1a], Of these, 195 had a nuclear expression pattern, and 3 showed cytoplasmic TDP-43 expression, while no formed inclusions were detected. In mtSODl-ALS tissues, 206 AHCs were counted with 199 showing a nuclear expression pattern and 4 with a cytoplasmic expression pattern [Figure 2.Id]. In mtTDP-43-ALS tissues, 112 AHCs were counted, of which 97 cells presented with a nuclear expression pattern, while 12 showed a cytoplasmic expression pattern [Figure 2.1b]. In mtFUS/TLS-ALS tissues, 88 AHCs were counted. Of these cells, 78 showed a nuclear expression pattern, while 4 showed evidence of cytoplasmic expression 
[Figure 2.1c]. In spinal cord tissues of fALS cases without known
Figure 2.1: Representative TDP-43 expression across all variants of ALS evaluated in this study.
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mutations, 348 AHCs were counted. Of these, 293 showed nuclear staining, while 47 showed cytoplasmic staining [Figure 2.1e]. In spinal cord tissues from cases of sALS without known mutations, we counted a total of 189 AHCs, 153 demonstrated a nuclear expression and 28 demonstrated cytoplasmic expression [Figure 2.If].
In all non-mtSODl variants of ALS, we saw clear evidence of TDP-43- positive formed cytoplasmic skeins and aggregates within AHCs [Figure 2.1]. Although 1.94% of cells quantified from mtSODl-ALS tissues showed cytoplasmic expression, no NCIs were observed. A summary of TDP-43 quantification data can be seen in Table 2.3; a summary of qualitative data across the panel can be found in Table 2.4 at the end of the results section.
The percentage of cells expressing TDP-43-positive nuclei was calculated, and the percentage of cells with a cytoplasmic expression of TDP-43 was also determined. The nuclear-to-cytoplasmic ratio was determined for each variant of ALS and for our neuropathologically normal control group 
[Figure 2.2] using the figures presented in Table 2.3. When analyzed, all cases of ALS showed significant nuclear-to-cytoplasmic expression ratios [p<0.001] with respect to neuropathologically normal controls [Figure 2.2].
FUS/TLS
Only qualitative observations were made for spinal cord tissues examined for FUS/TLS immunoreactivity. Control tissue showed FUS/TLS- positive nuclear staining [Figure 2.3a], which was also the most common type
Type AHCsCounted# NuclearExpression# NuclearMean* CytoplasmicExpression# CytoplasmicMean* Nuclear Mean: Cytoplasmic Mean NCIs?
Control 198 195 0.977 3 0.01 97.67 No
mtSODl-ALS 206 199 0.96 4 0.025 38.40 No
mtFUS/TLS-ALS 88 78 0.933 4 0.053 17.50 Yes
mtTDP-43-ALS 112 97 0.878 12 0.093 9.49 Yes
fALS, no known mutations 348 293 0.834 47 0.143 5.85 YessALS, no known mutations 189 153 0.828 28 0.127 6.54 Yes
Table 2.3: Summary of TDP-43 quantification data
* Means were calculated by averaging the percentage of cells with nuclear or cytoplasmic expression from each case within control and ALS variants.
Figure 2.2: A TDP-43 nucleocytoplasmic redistribution occurs in ALS tissues, but not in healthy controls.
Cells with clear evidence of a nucleolus [A, B, arrows] were scored. Each cell received a score for nuclear expression and cytoplasmic expression. A is representative of a motor neuron with nuclear expression, while B is representative of a motor neuron with cytoplasmic expression. When the ratio of the mean of cells expressing nuclear TDP-43 staining to the mean of cells expressing cytoplasmic TDP-43 staining is calculated, there is evidence of a statistically significant [P<0.001] intracellular nucleocytoplasmic redistribution occurring in every variant of ALS examined [C]. Means were calculated by averaging the percentage of cells with either a nuclear or cytoplasmic expression from each case across each variant of ALS and controls. When further analyzing the data, the ratio calculated from mtSODl-ALS cases was significantly higher than that of cases of mtTDP-43-ALS [P<0.01], and fALS and sALS without any known mutations [P<0.001]. Interestingly, the difference in the redistribution ratios calculated for cases of mtSODl-ALS and mtFUS/TLS- ALS were not found to be statistically significant; however, there does appear to be a trend approaching significance. Statistical analysis was done using a one­way ANOVA with a Tukey-Kramer Multiple Comparisons post-hoc test.
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Control mtSODl mtFUS/TLS mtTDP-43 fALS sALS
Immunohistochemistry was performed using an antibody against FUS/TLS [Rabbit Polyclonal, Proteintech (Cat # 11570-1-AP), 1:90, 20 hours, 4°C]. The typical FUS/TLS staining pattern observed in healthy motor neurons is almost exclusively nuclear. This is represented by an arrow and can be seen in A. Similarly, mtSODl-ALS cases did not appear to have any type of NCIs [D]. NCls were seen in all non-mtSODl variants of ALS. Interesting to note is the typicalfilamentous expression pattern observed in cases of mtFUS/TLS-ALS [C] as well/ 'as in cases of fALS without any known mutations [E]. Also commonly seen amongst cases of mtTDP-43-ALS [B] and cases of sALS without any known mutations [F] are densely packed FUS/TLS-positive NCIs. The scale bar
Figure 2.3: Representative FUS/TLS expression across all variants of ALS
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of FUS/TLS immunoreactivity observed in mtSODl tissue [Figure 2.3d]. Evidence of FUS/TLS-positive skeins and aggregates in all non-mtSODl variants of ALS was found [Figure 2.3b,c,e,f].
RGNEF
Qualitative observations were made for RGNEF expression. The normal staining pattern is either the presence of a coarse granular expression pattern, or a uniform cytoplasmic expression pattern. There was evidence of RGNEF- positive skeins and aggregates in all non-mtSODl variants of ALS [Figure 
2.4b,c,e,f]. Mutant S0D1 AHCs never showed evidence of RGNEF-positive NCls 
[Figure 2.4d], and tended to have a staining pattern resembling that of AHCs from neuropathologically normal controls [Figure 2.4a].
SOD1
Qualitative observations were made for our analysis of SOD1 stained spinal cord tissue. We observed cytoplasmic SODl-positive expression in AHCs from mtSODl-ALS tissue [Figure 2.5d]. Similar to healthy controls, we did not observe SODl-positive inclusions in any non-mtSODl variants of ALS [Figure 
2.5a,b,c,e,f].
Ubiquitin
Our data for ubiquitin staining of spinal cord tissue was collected in a semi-quantitative manner. We did not observe any cytoplasmic ubiquitin- positive NCIs in our neuropathologically normal control group or in our
An immunohistochemical analysis was performed using a novel antibody against RGNEF [Goat Polyclonal, 21 Century Biochemicals, 1:500, 20 hours, 4°C]. The typical staining pattern observed in AHCs of healthy controls is weakly cytoplasmic [A]. Interestingly, another very commonly observed RGNEF expression pattern within healthy controls and ALS is that of coarse granular polysomes. Polysomes are clusters of ribosomes that synthesize proteins from multiple sites on a transcript [arrows, D] [see Chapter 3]. RGNEF-positive polysomes are commonly seen across all variants of ALS, and was the only type of intraneuronal pathology seen in mtSODl-ALS cases in this study [D]. Within the AHCs of other types of ALS, however, can be observed RGNEF-positive NCIs. Filamentous NCIs were found in mtFUS/TLS-ALS cases as well as in the sALS and fALS cases without any known mutations [C, E, and F]. Cases of mtTDP-43- ALS did not contain filamentous RGNEF-positive inclusions, but there was evidence of RGNEF sequestration into dense cytoplasmic aggregates [B]. The
Figure 2.4: Representative RGNEF expression across all variants of ALS
evaluated in this study.
scale bar represents 20 pm.
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An expression pattern analysis was done using an antibody against S0D1 [Rabbit Polyclonal, Enzo Lifesciences (Cat # ADI-SOD-lOO), 1:500, 20 hours, 4°C], the results of which support previously published studies. SODl-positive NCls were never observed in healthy control cases, in mtTDP-43-ALS, in mtFUS/TLS-ALS, or in fALS and sALS cases without any known mutations. SOD1 expression was evident, however, in cases of mtSODl-ALS. The most commonly observed SODl-positive pathology within AHCs of mtSODl-ALS cases is diffuse intraneuronal non-filamentous inclusions, which can be seen in D. The scale bar in this figure represents 20 pm.
Figure 2.5: Representative S0D1 expression across all variants of ALS
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mtFUS/TLS group [Figure 2.6a,c]. We observed cytoplasmic ubiquitin-positive NCls in the mtTDP-43, mtSODl, fALS, and sALS variants of ALS [Figure 
2.6b,d,e,f]. For AHCs in the mtTDP-43 genetic variant of ALS, we observed greater than 10 cells per spinal cord section expressing cytoplasmic ubiquitin- positive inclusions.
p62
Our data collection for p62 staining of spinal cord tissue was done in a semi-quantitative manner. P62 immunoreactivity in our neuropathologically normal control group was rare, but included small, punctate grains around the nuclear membrane [Figure 2.7a]. We observed cytoplasmic p62-positive NCIs in every variant of ALS [Figure 2.7b-f]. For AHCs from patients with mtTDP- 43-ALS, fALS, and sALS, we observed greater than 10 cells per spinal cord section that expressed cytoplasmic p62-positive inclusions.
Optineurin
Across all the genetic variants of ALS in our panel in addition to fALS and sALS cases without any known mutations, and in our neuropathologically normal control group, we observed a fine granular AHC staining pattern associated with optineurin [Figure 2.8a-f]. No optineurin-positive NCIs were observed in any MN analyzed.
An immunohistochemical analysis was done using an antibody against ubiquitin [Mouse Monoclonal, Millipore [Cat # MAB-1510], 1:500, 20 hours, 4°C]. Typical staining in healthy control cases was non-existent [A]. No ubiquitin-positive NCIs were observed in motor neurons of cases of mtFUS/TLS-ALS [C], which may be due to a case selection bias, as these have been reported in other studies [Deng et a l, 2010]. Ubiquitin-positive NCIs were observed in mtTDP-43-ALScases [B], mtSODl-ALS cases [D], fALS cases without known mutations [E] and/sALS cases without known mutations [F]. Like the NCIs observed using antibodies against other proteins, both filamentous [arrows] and densely aggregated [arrow heads] NCIs were observed throughout our panel. The scale
Figure 2.6: Representative ubiquitin expression across all variants of ALS
evaluated in this study.
bar represents 20 pm.
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Immunohistochemistry was performed using an antibody against p62 [Rabbit Polyclonal, Enzo Lifesciences (Cat # PW9860), 1:1000, 20 hours, 4°C] and NCIs were commonly observed in all genetic variants of ALS analyzed, as well as in cases of fALS and sALS without any known mutations. As observed in NCIs using antibodies against other proteins, NCIs can take the form of both/either filamentous [arrow] and/or densely aggregated inclusions [arrow head]. In neuropathologically normal control tissues, p62 immunoreactivity was rarely observed, but if it was present, it was expressed faintly in the nucleus [A]. The
Figure 2.7: Representative p62 expression across all variants of ALS evaluated
in this study.





An expression analysis was performed using immunohistochemical methods with 2 antibodies against optineurin [Rabbit Polyclonal, Abeam [Cat # ab79110 & ab23666), 1:150, 20 hours, 4°C]. An analysis of the expression patterns revealed an identical fine granular staining pattern across all genetic variants of ALS, both fALS and sALS without any known mutations, and neuropathologically normal controls. Although the fine granules could occasionally be more densely packed [B, D, arrows], the pattern was observed
s'to be identical in every case. Of note is the observation that the fine granules could often be seen concentrated in a perinuclear and/or a pericellular fashion [A]. This was a phenomenon observed in AHCs from both healthy control and ALS cases. The scale bar represents 20 pm.
Figure 2.8: Representative optineurin expression across all variants of ALS






Our data analysis of pNFH [SMI31] staining of spinal cord tissue was done in a semi-quantitative manner [Table 2.4, end of results section]. SMI31 staining in our mtSODl tissues revealed the presence of axonal globules, which are neuroaxonal inclusions that are less than 20 pm at the largest diameter, as defined by Carpenter (Carpenter, 1968] [Figure 2.9d]. The presence of these neuroaxonal globules was also the only expression pattern observed in our neuropathologically normal control group [Figure 2.9a]. Large [>30pm diameter] SMI31-positive neuroaxonal spheroids were detected in all non- m tSODl variants of ALS [Figure 2.9b,c,e,f].
Peripherin
Data collection of peripherin staining of spinal cord tissue was done in a semi-quantitative manner [Table 2.4, end of results section]. We did not observe any cytoplasmic peripherin-positive inclusions in neuropathologically normal controls [Figure 2.10a] or in AHCs from mtSODl-ALS cases [Figure 
2.10d]. We observed cytoplasmic peripherin-positive inclusions in AHCs of all non-mtSODl variants of ALS, and in fALS and sALS cases without any known mutations [Figure 2.10b,c,e,f].
Mutant SOD1 Tissues
As mentioned above, expression patterns for most proteins across our panel were found to be unique in mtSODl variants of ALS when compared with
An immunohistochemical analysis was performed using an antibody against phosphorylated high molecular weight neurofilament [Mouse Monoclonal, Sternberger Monoclonals [Cat # SMI-31R), 1:30,000, 20 hours, 4°C]. A classical pathology of ALS, consistent with the definition of Carpenter [Carpenter, 1968), is the presence of neuroaxonal spheroids that have been defined as axonal inclusions greater than or equal to 30 pm. Large neuroaxonal spheroids were seen in the non-mtSODl genetic variants of ALS [B, C], as well as in fALS and sALS cases that have no known mutations [E, F]. Also defined by Carpenter are neuroaxonal globules, which are axonal inclusions smaller than 20 pm. These were commonly observed in healthy control cases [A] as well as in cases of mtSODl-ALS [D]. The scale bar represents 20 pm.
Figure 2.9: Representative pNFH expression across all variants of ALS




Immunohistochemistry using an antibody against peripherin [Rabbit Polyclonal, Millipore (Cat # Abl530], 1:500, 20 hours, 4°C] was performed and an analysis revealed the presence of NCls in the non-mtSODl genetic variants of ALS [B, C] as well as in cases of fALS and sALS without any known mutations [E, F]. Unlike NCIs observed using antibodies against other proteins, peripherin-positive NCIs were only observed to be densely aggregated, and never filamentous. These dense cytoplasmic aggregates are highlighted throughout this figure with arrows. No peripherin-positive NCIs were evident in mtSODl-ALS cases [D] or in neuropathologically normal controls [A]. The scale bar represents 20 pm.
Figure 2.10: Representative peripherin expression across all variants of ALS
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RNA Binding Proteins Other ALS-Associated Proteins
Variant TDP-43 FUS/TLS RGNEF SOD1 Ubiquitin p62 Peripherin pNFH OptineurinControl N N N N - - - - -mtSODl-ALS N N N Y + + - - -mtTDP-43-ALS Y Y Y N +  + +  + + + -mtFUS/TLS-ALS Y Y Y N - + + + -fALS, no known mutations Y Y Y N + +  + + + -sALS, no known mutations Y Y Y N + +  + + + -
Table 2.4: Summary of neuronal cytoplasmic inclusions across the variants of ALS evaluated in this study.-VA summary of staining results of each antibody for each genetic variant of ALS analyzed in this study. Y = yes [presence of NCIs], N = no [absence of NCIs], + = presence of selected pathology, but less than 10 instances per section [both anterior horns]. ++ = 10 or more instances of selected pathology per section. -  = absence of selected pathology. All "Other ALS- Associated Proteins" were evaluated for the presence or absence of NCIs. Phosphorylated NFH was evaluated for the presence of neuroaxonal spheroids greater than or equal to 30 pm at smallest diameter. 105
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other variants of ALS and controls. Antibodies against the RNA binding proteins TDP-43, FUS/TLS, and RGNEF did not label any NCIs, and expression patterns for these proteins matched those seen in neuropathologically normal controls. SOD 1-positive inclusions were detected in mtSODl tissues, but not in any other genetic ALS variants, or in neuropathologically normal controls. Ubiquitin and p62-positive NCIs were observed in mtSODl-ALS tissues, perhaps marking SODl-positive inclusions for proteasome degradation. There was no evidence of any differential optineurin expression in mtSODl-ALS cases. The intermediate filament proteins peripherin and pNFH revealed the presence of pathological NCIs only in non-mtSODl variants of ALS. Large pNFH-positive neuroaxonal spheroids were not observed in mtSODl-ALS cases, nor were peripherin-positive NCIs.
Discussion and Concluding Remarks
With the discovery of the mtSODl association with a significant proportion of fALS cases, there was a concrete target to attempt to unravel the pathogenesis of ALS. With the subsequent discovery of mutations in TARDBP and FUS/TLS in some fALS families, the field began to target RNA binding proteins as contributors to ALS pathogenesis. After optimizing antigen retrieval, titres, and protocols for all of the antibodies used in this study, we examined our panel of diverse genetic variants of ALS as well as cases of fALS and sALS without any known mutations with a selection of 9 ALS-associated
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protein markers that are a contemporary focus of ALS research. We have determined that mtSODl-ALS is a pathologically unique variant of the disease in that there is differential protein expression seen between mtSODl-ALS and the other variants of ALS analyzed in this study. This is important given the linkage of these RNA binding proteins to familial forms of ALS and the subsequent association of ALS to altered RNA metabolism. Although mtSODl-ALS has a differential expression of RNA binding proteins, it is important to consider the RNA binding properties of the mutant form of S0D1, and thus the classification of mtSODl-ALS as a disease of altered RNA metabolism as well.
As summarized in Table 2.3, TDP-43-positive skeins and aggregates were seen across all non-mtSODl variants of ALS [Figure 2.1, Table 2.3]. This is in contrast to an earlier observation that TDP-43-positive cytoplasmic aggregates can be observed in mtSODl-ALS tissue (Robertson etal., 2007). The key difference between these studies is that the present study used DAB immunohistochemistry and visualized protein deposition at the light microscopy level, whereas the study by Robertson et al. (Robertson et a i, 2007) used immunofluorescent staining and visualized protein deposition with confocal microscopy. The level of detection differences in these 2 techniques accounts for this discrepancy. While confocal microscopy is widely available to researchers, it is prohibitive in clinical settings due to time constraints and lack of automated staining and visualization techniques. The techniques employed here could be automated, which would allow for rapid slide processing and give reproducible and easily discernible staining patterns. Our goal was to provide
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an analytic algorithm that would be widely applicable using routine immunohistochemistry.
We also made the observation that the nucleocytoplasmic redistribution of TDP-43 occurs in all variants of ALS, but occurs at a significantly higher rate in mtTDP-43-ALS, fALS, and sALS when compared to mtSODl-ALS [Figure 2.2]. Although the redistribution results between mtSODl-ALS and mtFUS/TLS-ALS were not statistically significant, there seems to be a trend towards increased TDP-43 nucleocytoplasmic redistribution in mtFUS/TLS-ALS cases as well 
[Figure 2.2]. This phenomenon has been shown to be a normal response toinjury in an axotomy mouse model and is reversible (Wang et a l, 2008; Moisse/
et a l, 2009). Another possibility is that this nucleocytoplasmic redistribution is a protein-level manifestation of a cellular repair mechanism. This may suggest that non-mtSODl variants of ALS engage in a more severe response to MN injury and will eventually recover, or it may be a pathological response and the initial stages of the formation of NCIs. An important distinction to draw, however, is the difference between cytoplasmic up-regulation of TDP-43, and the presence of cytoplasmic intraneuronal TDP-43-positive inclusions. Where an up-regulation is known to be a normal injury response, the presence of formed inclusions is thought to be pathological. In either case, the divergent pathological expression patterns between mtSODl-ALS and all other variants of ALS suggest the possibility of divergent pathways of aberrant RNA metabolism linked to disease pathogenesis despite indistinguishable clinical phenotypes.
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Further pathological observations of RNA binding proteins made in the present study are in agreement with previously published studies. Firstly, the presence of FUS/TLS-positive cytoplasmic inclusions in all non-mtSODl variants of ALS [Figure 2.3, Table 2.4] concurred with data presented by Deng 
et al. [Deng et a l, 2010). We made note of the importance of antigen retrieval and antibody selection discussed by Deng et al. as well as the observation that many FUS/TLS-positive NCIs were also immunoreactive with antibodies against p62, ubiquitin, and TDP-43.
Detection using an antibody against SOD1 revealed immunoreactive inclusions only in mtSODl-ALS cases [Figure 2.5]. This is in line with previous observations that mtSODl-ALS cases have SODl-positive NCIs (Shibata et al., 1996; Kato et a l, 1999). The lack of SODl-positive inclusions in cases of sALS without known mutations in the present study could be due to case selection bias, as only 6 such cases were examined, and the finding is known to be uncommon.
Finally, we evaluated a novel RNA binding protein [RGNEF] in this study. Similar to the findings for both TDP-43 and FUS/TLS, in all non-mtSODl variants of ALS, we observed RGNEF immunoreactive NCIs. These inclusions have also been found to co-localize with ubiquitin and p62 [see Chapter 3]. This suggests that RGNEF-positive NCIs can be targeted for proteasomal degradation in ALS cases, which is similar to other RNA binding proteins; a common theme thus emerges.
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There also was evidence of NCIs of ubiquitin [Figure 2.6] across all non- mtFUS/TLS variants of ALS, and of p62-positive inclusions across all variants of ALS [Figure 2.7]. As previously discussed, both are markers of protein degradation. The presence of ubiquitin or p62-positive NCIs suggests that the proteins being targeted are being degraded by the proteasome complex. Ubiquitin-positive NCIs have previously been reported in all non-mtSODl variants of ALS (Deng et al., 2010). Past studies have determined p62 to be an alternate marker of proteasome degradation, and suggestions have been made regarding its superiority over ubiquitin (Mizuno et a l, 2006). Interestingly, we observed p62-positive NCIs more reliably than detection with ubiquitin. For this reason, as well as our observation of more intense immunoreactivity using the antibody against p62 compared with ubiquitin across our panel, we have selected our antibody against p62 to be a more reliable and robust marker of protein degradation than ubiquitin.
Our results revealed no optineurin-positive inclusions across our panel of cases [Figure 2.8], in contrast to past work (Maruyama et al., 2010). Maruyama and colleagues noted optineurin-positive inclusions in mtSODl variants of ALS and suggested that optineurin may be the unifying protein in seemingly divergent pathways of MN degeneration. Taken with data presented here, we suggest that mtSODl-ALS is a pathologically distinct variant of ALS. More recent work (Hortobagyi et al., 2011) has found that optineurin does not appear to be a pathologically unifying protein across variants of ALS.
I l l
The intermediate filament proteins peripherin and NFH highlighted pathology in all non-mtSODl genetic variants of ALS as well as in cases of fALS and sALS without known mutations [Figures 2.9, 2.10]. As mentioned above, we analyzed pNFH immunohistochemistry for the presence of large [>30 pm at smallest diameter] neuroaxonal spheroids [Wohlfart, 1959; Carpenter, 1968). A NF marker is important to this study due to the focus on NFL mRNA binding proteins and the finding that NF subunit stoichiometry can be altered in ALS, but not in controls [Bergeron et a l, 1994; Wong et a l, 2000; Menzies et a l, 2002). Peripherin was found to form NCls in non-mtSODl-ALS cases as well as in cases of fALS and sALS without any known mutations. Intermediate filament pathology is a classical hallmark of ALS, and our observation that intermediate filament pathology could only be seen in non-mtSODl variants of ALS lends further support to our finding that mtSODl-ALS is a pathologically unique variant of the disease.
This is the first work to comprehensively focus on the contemporary markers of ALS across a panel of diverse variants of the disease and examine specific proteins for pathology to determine if these variants of ALS can be identified through routine immunohistochemical methods. It appears that cases harbouring mutations in S0D1 can be identified by their immunohistochemical characteristics: p62-positive NCls that are negative for the 3 non-mtSODl RNA binding proteins. We thus recommend that all ALS cases be studied by immunohistochemistry using these antibodies, and if this pattern is found, then a genotypic analysis should be done to confirm the presence of mtSODl-ALS.
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Chapter 3: Amyotrophic lateral sclerosis is a disease of altered 
RNA metabolism characterized by the aberrant expression of 
RGNEF and other RNA binding proteins
Brian A. Keller, Kathryn Volkening, Cristian Droppelmann, Michael J. Strong
A version of this chapter is in preparation and will be submitted for publication.
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Abstract
Amyotrophie lateral sclerosis [ALS] is a fatal neurological disease in which those affected experience a selective loss of motor neurons, leading to muscle paralysis and death within 3-5 years of symptom onset. The classic pathological hallmark of ALS is the presence of intermediate filament-positive neuronal cytoplasmic inclusions [NCIs] in the anterior horn of the spinal cord. Accompanying this pathology is a decrease in the steady state mRNA levels of low molecular weight [68 kDa] neurofilament [NF] mRNA, which has been hypothesized to alter the stoichiometry of the NF polymer. Thus, proteins regulating the stability of NFL mRNA are of considerable interest. We recently identified RGNEF, a human homologue of the murine pl90RhoGEF, which is a protein known to regulate the stability of murine NFL mRNA. Because NFL mRNA binding proteins [ex. TDP-43, FUS/TLS, mtSODl, 14-3-3] have been shown to form NCIs in ALS, we sought to determine if RGNEF also forms pathological inclusions in ALS. To do so, we developed polyclonal and monoclonal antibodies against RGNEF. We observed RGNEF-positive NCIs only in ALS anterior horn cells [AHCs], and not in healthy controls. RGNEF immunoreactive inclusions were also immunoreactive to p62 and ubiquitin, suggesting that its degradation is also impaired. Similar to TDP-43, we also observed that RGNEF is present in transport granules, stress granules, and processing bodies. We observed that some RGNEF-positive NCIs are also immunoreactive for TDP-43 and FUS/TLS, and a strong degree of co-localization is evident within some cells. Overall, our data indicates that RGNEF is actively
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involved in RNA metabolism, can be aberrantly expressed in ALS, and is a possible contributor to disease pathogenesis.
Introduction
Amyotrophic lateral sclerosis [ALS] is a progressive, motor neuron [MN] selective disease that is generally fatal due to respiratory failure within 5 years of symptom onset (Logroscino et al., 2008). The cause(s) of ALS remain to be elucidated, although it is generally accepted that there are multiple factors contributing to its pathogenesis. ALS is also considered to be a multisystems disorder, with the presence of a frontotemporal syndrome observed in up to 50% of patients [Strong, 2010). Approximately 10% of cases are inherited [familial ALS; fALS], Amongst these cases, the most common genetic mutations are present in the gene encoding Cu/Zn-superoxide dismutase [SOD1] [Rosen et 
a l, 1993). More recently, mutations in the genes encoding TAR-DNA binding protein of 43 kDa [TDP-43] [Kabashi et al., 2008; Rutherford et a l, 2008; Sreedharan et a l, 2008; Van Deerlin et a l, 2008; Corrado et al., 2009; Daoud et 
a l, 2009; Del Bo etal., 2009), and fused in sarcoma/translocated in liposarcoma [FUS/TLS] [Lagier-Tourenne and Cleveland, 2009; Vance e ta l, 2009; Corrado et 
a l, 2010) have also been identified. Interestingly, TDP-43, FUS/TLS, and mutant [mt] SOD1 are all known to bind RNA and help to regulate its metabolism (Strong, 2010).
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A classic pathological hallmark of ALS is the presence of intermediate filamentous aggregates within degenerating MNs. These include aggregates of peripherin (Migheli et a l, 1993; Beaulieu et a l, 2000; He and Hays, 2004), alpha-internexin (Wong et a l, 2000), and neurofilament [NF] (Julien, 1999; Beaulieu et a l, 2000; Strong et a l, 2005). There are 3 subunits of NF, which correspond to their molecular weights [68 kDa NFL, 160 kDa NFM, 200 kDa NFH]. The key to subunit polymerization to form functional NF is the stoichiometric ratios of NFL, NFM, and NFH with respect to one another. Interestingly, in the case of NF NCIs seen in ALS patients, NFL mRNA levels are significantly suppressed with respect to steady-state mRNA levels of NFM and NFH (Bergeron et a l, 1994; Wong et a l, 2000; Menzies et a l, 2002; Strong, 2010). Further, the RNA binding proteins introduced above, TDP-43 (Buratti and Baralle, 2001; Strong et a l, 2007), FUS/TLS (Strong, 2010; Ticozzi et a l, 2010), and mtSODl (Strong, 2010), are known to interact with NFL mRNA and modulate its stability. Also, both TDP-43 and FUS/TLS have been shown to form ubiquitinated NCIs in ALS, but not in controls, suggesting a possible role for them in the pathogenesis of ALS (Arai et a l, 2006; Neumann et a l, 2006; Deng e ta l, 2010).
P190RhoGEF is a protein known to alter the stability of murine NFL mRNA through binding to a destabilizing element in the 3’ untranslated region (Canete-Soler et a l, 2001). P190RhoGEF can co-localize with NFL aggregates, but not with NFL subunits assembled in functional NF arrays (Lin et a l, 2005). Further, the same study showed that aggregation of NFL is associated with the
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decrease in steady-state levels of NFL mRNA, and that siRNA silencing of pl90RhoGEF increases NF polymerization and decreases NFL aggregation. For these reasons, we searched for a human homologue of pl90RhoGEF, and discovered RGNEF to be a highly homologous protein (Volkening et al., 2010]. Initial findings regarding RGNEF include the expression of its RNA in both brains and spinal cords, and that RGNEF and NFL mRNA interact directly in 
vitro in lysates from ALS-affected spinal cords, but not in lysates from healthy controls (Volkening et al., 2010). RGNEF is the first described link between ALS and an RNA binding protein that is also of an important role in cell signaling via the RhoA signaling cascade (Droppelmann et al., Submitted, 2011). This study will, for the first time, characterize RGNEF expression within human ALS spinal motor neurons.
Increasingly, RNA metabolism is being regarded as a very dynamic process. Gene expression within a MN occurs under somatotopic direction, meaning that translation occurs at the site within the cell where the protein will be immediately needed. For this to occur successfully, several post- transcriptional modifications must first take place -  mRNA processing, which includes the addition of a 7-methylguanosine cap to the 5' end of the transcript and the addition of a 3' poly (A) tail, splicing, editing, and stabilization (Bolognani and Perrone-Bizzozero, 2008). Following post-transcriptional modifications, mRNA is packaged into a ribonucleoprotein [RNP] complex that includes some necessary translational machinery, which is then shipped to the site of protein synthesis (Strong, 2010). These RNP complexes, which can be
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identified as RNA granules, can take on several identities depending on the cell’s health and its need for their contents. Transport granules are one such identity. Transport granules are RNA granules that are being directed through the cell to the location of protein synthesis. An accepted molecular marker of these granules is Staufen (Kim and Kim, 2006). On the other hand, when a cell is under stress and translation is inhibited, RNA granules take on a molecule of TIA-1 and can be referred to as stress granules (Kedersha et a l, 1999). Lastly, when mRNA is going to be degraded, the RNA granule becomes a mRNA processing body [P-body], characterized by the presence of the exoribonuclease XRN-1 (Chang et a l, 2011). Increasing evidence is pointing to the fluid nature of the relationship between stress granules and P-bodies (Kedersha et a l, 2005; Barbee e ta l, 2006; Anderson and Kedersha, 2008).
As reports have indicated, neuroinflammation is a natural aspect of the innate immune response within the nervous system, and innate immunity has been associated with ALS (Moisse and Strong, 2006). Attenuation of inflammation in animal models delays the onset of ALS symptoms and extends survival (Moisse and Strong, 2006). Also, descriptions of microglial (Lampson 
et al., 1990; Troost et a l, 1990; McGeer et a l, 1991; Kawamata et a l, 1992; Troost et a l, 1993; Wilson et a l, 2001; Henkel et a l, 2004; Solomon et a l, 2006) and astrocytic (Engelhardt and Appel, 1990; Kushner et a l, 1991; Kawamata et 
al., 1992; Engelhardt et al., 1993; Nagy et a l, 1994; Schiffer et a l, 1996; Hall et 
a l, 1998; Alexianu et a l, 2001) activation have been well documented in ALS. Thus, it is of considerable interest to understand proteins that may mediate the
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glial response and improve prognosis for ALS patients. In an effort to determine if RGNEF may be a potential mediator of gliosis in ALS, this study sought to determine the relationship between RGNEF, microglia, and astrocytes. In addition, we have sought to investigate the relationship between RGNEF and the markers of RNA metabolism mentioned above. Finally, we have examined the association between RGNEF and proteasome degradation in ALS cases as well as the association between RGNEF and 2 other ALS-associated, RNA binding proteins: TDP-43 and FUS/TLS.
Materials and Experimental Procedures
RGNEF Antibody Development and Optimization
A goat polyclonal antibody against RGNEF was produced by 21st Century Biochemicals [260 Cedar Hill Street, Marlboro, MA, USA 01752] using the immunogenic peptide sequence 1567-INEALVQMSFNTFNKLNPSV-1586. The antibody specificity was determined by comparing the expression patterns of immunohistochemistry using the RGNEF antibody to staining with the antibody and blocking peptide. Performing immunolabeling with a range of antibody titres optimized sensitivity. The staining results were further optimized using different methods of antigen retrieval.
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Immunohistochemistry
Six-micrometer sections of formalin-fixed, paraffin-embedded spinal cord tissue were warmed at 63°C for 30 minutes and rehydrated through an ethanol series to lxPBS with 5-minute washes [xylenes, 1:1 xylenes:ethanol, 100% ethanol, 95% ethanol, 75% ethanol, 50% ethanol, lxPBS]. Following rehydration, sodium citrate buffer [lOmM Sodium Citrate, 0.05% Tween 20, pH 6] antigen retrieval was performed using a 2100 Retriever chamber [Pick Cell Laboratories, Lelystad, Netherlands]. Sections were washed 3 times for 5 minutes each using lxPBS and then treated for 5 minutes at room temperature with 3% H2O2 to block endogenous peroxidase activity. After 3 additional 5- minute washes with lxPBS, the sections were blocked for 60 minutes in 5% bovine serum albumin [Roche Diagnostics, Mannheim, Germany] in water. Following blocking, the sections were incubated with a polyclonal antibody against RGNEF [21st Century Biochemicals (Ac-INEALVQMSFNTFNKLNPSVC-N), 1:500] for 20 hours at 4°C. The sections were then washed 3 times for 5 minutes each in lxPBS and were then incubated with Biotinylated Goat IgG [Vectastain Elite ABC Kit, Vector Laboratories, Cat # PK-6105, Burlingame, CA] for 60 minutes at room temperature at a titre of 1:500. Following 3 additional washes of 5 minutes each in lxPBS, the tissues were incubated with the avidin/biotin enzyme complex solution [Vectastain kit], washed in lxPBS 3 times for 5 minutes each and treated with 3,3'-diaminobenzidine [Sigma- Aldrich Canada, Oakville, ON]. Nuclear counterstaining was then performed using Modified Harris Formula Haematoxylin [Ricca Chemical Company,
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Arlington, TX]. Sections were dried, mounted with Cytoseal 60 mounting medium [Richard-Allan Scientific, Kalamazoo, Ml], observed using a BX45 light microscope [Olympus, Markham, ON], and photographed with a Q Color 3 camera [Olympus, Markham, ON].
Immunofluorescence
Formalin-fixed, paraffin-embedded spinal cord tissues were treated for 15 hours with 365 nm ultraviolet light to minimize the autofluorescence of lipofuscin. Tissues were warmed at 63°C for 30 minutes and rehydrated through a series of ethanol washes [xylenes, 1:1 xylenes:ethanol, 100% ethanol, 95% ethanol, 75% ethanol, 50% ethanol, lxPBS], Following rehydration, antigen retrieval was performed using sodium citrate solution [lOmM Sodium Citrate, 0.05% Tween 20, pH 6] in a 2100 Retriever chamber [Pick Cell Laboratories, Lelystad, Netherlands]. The sections were washed 3 times for 5 minutes each using lxPBS and then treated for 5 minutes at room temperature with 3% H2O2 to block endogenous peroxidase activity. Following 3 additional 5-minute washes in lxPBS, the sections were blocked for 60 minutes in 5% bovine serum albumin [Roche Diagnostics, Mannheim, Germany] in water. After blocking, the sections were incubated with the appropriate antibodies for 20 hours at 4°C [Table 3.1]. The sections were then washed 3 times for 5 minutes each in lxPBS and were then incubated with the appropriate fluorescent- conjugated secondary antibody for 60 minutes at room temperature at a titre of
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Antibody Titre Source Secondary Antibody
RGNEFGoat Polyclonal 1:75 (IF) 1:500 (IHC)
21st Century Biochemicals (Antigen: Ac- INEALVQMSFNT- FNKLNPSVC-N)
Invitrogen, Alexa Fluor® 488, Donkey a-Goat, Cat # A11055
TDP-43Rabbit Polyclonal 1:500 Proteintech (Cat # 10782-2-AP) Invitrogen, Alexa Fluor® 555, Donkey a-Rabbit, Cat # A31572FUS/TLS Rabbit Polyclonal 1:90 Proteintech (Cat # 11570-1-AP) Invitrogen, Alexa Fluor® 555, Donkey a-Rabbit, Cat # A31572p62Rabbit Polyclonal 1:1000 Enzo Lifesciences (Cat # PW 9860) Invitrogen, Alexa Fluor® 555, Donkey a-Rabbit, Cat # A31572UbiquitinMouseMonoclonal 1:500 Millipore (Cat # MAB-1510) Invitrogen, Alexa Fluor® 568, Donkey a-Mouse, Cat # A10037L26Rabbit Polyclonal 1:1000 Abeam (Cat # ab59652) Invitrogen, Alexa Fluor® 555, Donkey a-Rabbit, Cat # A31572StaufenRabbit Polyclonal 1:250 Abeam (Cat # ab50914) Invitrogen, Alexa Fluor® 555, Donkey a-Rabbit, Cat # A31572TIA-1MouseMonoclonal 1:100 Abeam (Cat # ab2712-250) Invitrogen, Alexa Fluor® 568, Donkey a-Mouse, Cat # A10037XRN-1Rabbit Polyclonal 1:100 BethylLaboratories (Cat # A300-443A) Invitrogen, Alexa Fluor® 555, Donkey a-Rabbit, Cat # A31572GFAPMouseMonoclonal 1:500 BD Pharmingen (Cat # 556330) Invitrogen, Alexa Fluor® 568, Donkey a-Mouse, Cat # A10037IBA-1Rabbit Polyclonal 1:1000 Wako Chemicals (Cat #019-19741) Invitrogen, Alexa Fluor® 555, Donkey a-Rabbit, Cat # A31572
Table 3.1: Details of use for each antibody in this study
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1:500 [Table 3.1]. Following 3 additional 5-minute washes in lxPBS, nuclear counterstaining was performed using Hoechst 33342 [Invitrogen, Cat # H21492] at a titre of 1:1000 in lxPBS for 7 minutes. Sections were partially dried, mounted with Immu-Mount mounting medium [Thermo Scientific, Kalamazoo, MI] and then observed at 400x magnification and photographed using an LSM 510 Meta Confocal Imaging System [Carl Zeiss Canada Ltd., Toronto, ON].
Protein Expression Analysis
We first characterized the expression of RGNEF within MNs and surrounding cells. We performed double immunolabeling assays using markers for RGNEF and the ribosomal protein L26, which has been shown to be an accurate marker of translationally active polysomes (Singhrao and Nair- Roberts, 2010]. After determining the normal expression patterns, we performed further double immunolabeling assays using antibodies against RGNEF and either p62 or ubiquitin, 2 markers of the proteasome-protein degradation pathway. For details of antibody usage, please refer to Table 3.1.
We were then interested in the interaction between RGNEF and the ALS- associated, RNA binding proteins TDP-43 and FUS/TLS within anterior horn MNs. To look at the interaction, we performed double immunolabeling experiments using antibodies against RGNEF and either TDP-43 or FUS/TLS. To determine if RGNEF plays an active role in the RNA metabolic pathway, we performed double immunolabeling using markers against transport granules
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[Staufen], stress granules [TIA-1], and P-bodies [XRN-1]. For details of antibody usage, please refer back to Table 3.1.
Finally, due to the role neuroinflammation plays in neuronal injury and ALS, we aimed to determine the interaction between RGNEF and glial cells in the anterior horn of the spinal cord. We performed double immunolabeling experiments using antibodies against RGNEF and either IBA-1 [microglia] or GFAP [astrocytes]. For details of antibody usage, please refer back to Table 3.1.
Protein Complex Immunoprecipitation/ Western Blot
Cloning o f full length RGNEF
The full RGNEF coding sequence was cloned by PCR using Pfu DNA polymerase [Fermentas, Burlington, ON, Canada]. The commercial RGNEF clone [GenBank B C 157846] M H S1768-99865695 [Open Biosystem] was used as a template. The RGNEF coding sequence was incorporated in the pcDNA3.1-myc-His [Invitrogen, Carlsbad, C A , USA] vector between the Kpn I/Xho I sites.
Transfection and Western blot
HEK293T cells were transfected with the pcDNA-C-Myc-RGNEF or pcDNA3.1-C-Myc-His [control cells] vector using Lipofectamine 2000 [Invitrogen, Carlsbad, C A , USA]. The cells were lysed with an NP40-based lysis buffer, and then a Protein Complex Immunoprecipitation [Co-IP] was performed for 60 minutes at room temperature using an antibody against RGNEF [Goat anti- RGNEF, 21st Century Biochemicals] and Sepharose A [GE Healthcare,
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Piscataway, NJ] as the protein carrier. Two Western Blots were performed: one using an antibody against L26 [1:2000] detailed in Table 3.1 above, and one using mouse monoclonal antibody against C-Myc [Cedarlane, Catalogue # CLX229AP, 1:2000].
Results
RGNEF Expression Analysis
We observed 2 very distinct expression patterns for RGNEF in control tissues -  a light uniform cytoplasmic expression pattern, and a coarse granular expression pattern [Figure 3.1]. To determine if the latter pattern was consistent with the association of RGNEF with translationally active polysomes, we did a double immunolabeling experiment using antibodies against RGNEF and the large ribosomal subunit protein, L26. In Figure 3.1, RGNEF is demonstrated to co-localize with L26. To further confirm this association, RGNEF was immunoprecipitated from HER 293T cells, and a Western Blot using an antibody against L26 was performed. We did not observe that RGNEF co- immunoprecipitated L26 [Figure 3.2a]. To confirm the efficacy of the techniques used for the immunoprécipitation and Western Blot, we used an RGNEF antibody to immunoprecipitate C-Myc-RGNEF, and then performed a Western Blot using an antibody against C-Myc [Figure 3.2b]. This blot had a positive band at the expected molecular weight. Taken together, these data
Figure 3.1: The characterization of the normal intraneuronal expression of RGNEF in neuropathologically normal control tissues.
Immunolabeling was performed using an antibody against RGNEF [Goat Polyclonal, 21st Century Biochemicals, 1:500 IHC, 1:75 IF, 20 hours, 4°C] and expression in neuropathologically normal control tissues revealed the presence of 2 commonly seen histological features: coarse granular polysomal granules [A, represented by arrows], and light cytoplasmic expression [B]. To test for the presence of RGNEF within translationally active polysomes, a double immunolabeling experiment was performed using an antibody against the large ribosomal subunit marker, L26 [Rabbit Polyclonal, Abeam (Cat # ab59567], 1:1000, 20 hours, 4°C]. Co-localization was evident [C]. The inset in Figure C shows a clear co-localization between RGNEF and L26. All scale bars represent20 pm.
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Figure 3.2: A protein-complex immunoprécipitation testing the interaction between RGNEF and L26 in complex followed by a Western Blot.
RGNEF was immunoprecipitated from HEK 293T cells, and a Western Blot using an antibody against L26 was performed [A]. RGNEF was not observed to co- immunoprecipitate L26. As a confirmation that the co-immunoprecipitation and Western Blot protocols were followed correctly, we used an antibody against RGNEF to immunoprecipitate RGNEF-C-Myc from HEK293T cells, and then performed a Western Blot using an antibody against C-Myc [B]. This blot contains a band at the expected molecular weight, confirming the validity of the protocol, and suggesting an indirect interaction between RGNEF and L26.
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suggest that the interaction between RGNEF and L26 is indirect, although they seem to be localized within the same complex.
It is known that RGNEF is an NFL mRNA binding protein (Volkening et 
a l, 2010), so double immunolabeling experiments were performed to determine associations between RGNEF and markers of RNA metabolism. As mentioned the markers of RNA metabolism used in this study were Staufen [transport granules], TIA-1 [stress granules], and XRN-1 [P-bodies]. RGNEF- positive RNA granules were observed in spinal MNs in ALS and controls. This co-localization was evident for all types of RNA granules evaluated in this study. Representative staining samples can be seen in Figure 3.3.
JFollowing this initial characterization of the normal expression of RGNEF, and knowing that RGNEF-positive NCIs can be formed in ALS but not in controls, it was necessary to determine if these NCIs were being targeted for degradation by the proteasome degradation pathway. To make this determination, double immunolabeling experiments were performed using antibodies against RGNEF and p62 [Figure 3.4] and against RGNEF and ubiquitin [Figure 3.5]. The presence of RGNEF-positive NCIs was very often associated with near complete co-localization between RGNEF and p62, and a strong co-localization could also be observed between RGNEF and ubiquitin. This co-localization suggests that aggregated intraneuronal forms of RGNEF are being targeted for degradation via the proteasome pathway.
Figure 3.3: The involvement of RGNEF within the RNA metabolic pathway through interactions with RNA granules.
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Figure 3.4: The co-localization between RGNEF and p62 suggests that RGNEF can be targeted for protein degradation via the proteasome degradation system.
Double immunolabeling experiments done using antibodies against RGNEF [Goat Polyclonal, 21st Century Biochemicals, 1:75, 20 hours, 4°C] and p62 [Rabbit Polyclonal, Enzo Lifesciences (Cat # PW 9860), 1:1000, 20 hours, 4°C] reveal a high level of co-localization in human spinal MNs. P62 immunoreactivity was not typically present within spinal MNs from healthycontrol tissue [A]. As described, the converse is true of spinal MNs from ALS/patients. RGNEF-positive NCIs can be immunolabeled with p62 [B]. The inset presents a selected area of the figure at high magnification that allows clear visualization of the RGNEF and p62 co-localization. The blue fluorescence staining is nuclear counterstaining using Hoechst 33342. All scale barsrepresent 20 pm.
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Figure 3.5: The co-localization between RGNEF and ubiquitin suggests that RGNEF can be targeted for protein degradation via the ubiquitin-proteasome degradation system.




Due to the focus on TDP-43 and FUS/TLS within the field of ALS, and given the presence of RGNEF-positive NCIs, double immunolabeling experiments were done in an effort to determine the relationship between RGNEF and these other NFL mRNA binding proteins. Double immunolabeling was done using antibodies against RGNEF and TDP-43, which revealed clear co-localization 
[Figure 3.6]. It was also possible for RGNEF and TDP-43 to be independently aggregated within the same cell without full co-localization. Additionally, double immunolabeling done using antibodies against RGNEF and FUS/TLS revealed the presence of near complete co-localization between the 2 proteins 
[Figure 3.7]. Analysis focusing on only the brightest 2% of pixels revealed a complex of co-localized RGNEF and FUS/TLS-positive fibrils [Figure 3.7].
Analysis of double immunolabeling experiments performed using antibodies against RGNEF and the glial markers revealed no expression of RGNEF within glial cells. Representative photographs of double immunolabeling experiments performed using antibodies against RGNEF and GFAP as well as antibodies against RGNEF and IBA-1 can be seen in Figure 3.8.
Discussion and Concluding Remarks
With considerable evidence mounting in support of ALS being regarded as a disease of altered RNA metabolism, adding another player to the short list of RNA binding proteins that can be aberrantly expressed in ALS is critical. The most striking finding from this study is the near complete co-localization
Double immunolabeling experiments were performed using antibodies against RGNEF [Goat Polyclonal, 21st Century Biochemicals, 1:75, 20 hours, 4°C] and TDP-43 [Rabbit Polyclonal, Proteintech [Cat # 10782-2-AP), 1:500, 20 hours, 4°C] in human spinal MNs. In spinal MNs from healthy control tissues, TDP-43 was always localized to the nucleus, and RGNEF was always expressed faintly throughout the cytosol or in a polysomal pattern [A]. The inset in Figure A is a higher magnification view of the clearly defined boundaries and the lack of interaction between nuclear TDP-43 and cytosolic RGNEF. Within ALS tissues, however, spinal MNs can present with RGNEF-positive NCIs that are also immunolabeled with TDP-43 [B]. The inset of this figure provides a higher magnification view of filamentous NCIs that are both RGNEF and TDP-43- positive and seem to be interacting within the MN. Nuclear counterstaining was done using Hoechst 33342 and can be seen in blue. All scale bars represent 20
Figure 3.6: A high degree of co-localization can be found between RGNEF and
TDP-43 within ALS motor neurons, but not within control motor neurons.
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Antibodies against RGNEF [Goat Polyclonal, 21st Century Biochemicals, 1:75, 20 hours, 4°C] and FUS/TLS [Rabbit Polyclonal, Proteintech (Cat # 11570-1-AP), 1:90, 20 hours, 4°C] were used in double immunolabeling experiments within human spinal MNs. Analysis revealed expected expression patterns in spinal MNs from healthy controls: mostly nuclear FUS/TLS with coarse granular RGNEF expression [A]. ALS tissue, however, contained spinal MNs that revealed high levels of co-localization between NCIs that were positive for both RGNEF and FUS/TLS [B]. This highly co-localized appearance is confirmed throughout multiple optical slices, and when looking at the brightest 2% of pixels of a co­localization channel throughout a Z-stack [B, inset], co-localization is clearly evident. Nuclear counterstaining, which was performed with Hoechst 33342, can be seen throughout this figure in blue. All scale bars represent 20 pm.
Figure 3.7: A high degree of co-localization between RGNEF and FUS/TLS
within ALS motor neurons, but not within control motor neurons.










Figure 3.8: The lack of glial RGNEF expression within the human spinal cord.
Double immunolabeling experiments were performed using antibodies against RGNEF [Goat Polyclonal, 21st Century Biochemicals, 1:75, 20 hours, 4°C] [green] and the microglial marker IBA-1 [Rabbit Polyclonal a-lBA-1, Wako Chemicals [Cat # 019-19741), 1:1000, 20 hours, 4°C] [red], as well as between RGNEF [green] and the astrocytic marker, GFAP [Mouse monoclonal a-GFAP, BD Pharmingen [Cat # 556330), 1:500, 20 hours, 4°C] [red] in human spinal MNs. RGNEF is not expressed in astrocytes in tissue from either healthy controls or from ALS cases [A, B]. Additionally, RGNEF is not expressed in microglia in tissue from either healthy controls or from ALS cases [C, D]. All photos in this figure are overlayed and include accurate expression of RGNEF, and either GFAP or IBA-1. The blue fluorescence staining is nuclear counterstaining using Hoechst 33342. All scale bars represent 20 pm.
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between RGNEF and p62, as well as between RGNEF and ubiquitin. This evidence suggests that RGNEF-positive NCIs are being targeted for protein degradation via the proteasome degradation system. In 2006, when evidence was first presented showing that TDP-43 was being targeted for degradation in this manner (Arai et a l, 2006; Neumann et al., 2006], the field of ALS quickly turned its focus to TDP-43 and the possibility of ALS being a TDP-43 proteinopathy. Now, with the knowledge that RGNEF and FUS/TLS-positive NCIs can be ubiquitinated in ALS, but not in controls, we are compiling convincing evidence that the misregulation of RNA is part of the pathogenicity of ALS, as opposed to the misregulation of a single RNA binding protein.
Recent work has shown FUS/TLS and TDP-43 interaction in a 
Saccharomyces cerevisiae yeast model expressing FUS/TLS and TDP-43, neither of which possess a yeast homologue (Kryndushkin et al., 2011]. We are not aware of any studies suggesting interaction between FUS/TLS and wild type TDP-43 in human tissue. There is evidence, however, indicating an interaction between mtTDP-43 and FUS/TLS in a human cell line (Ling et a l, 2010]. This is the first evidence suggesting a convergence of 2 potentially pathogenic pathways in ALS. Interestingly, RGNEF-positive NCIs were shown to very intensely co-localize with FUS/TLS [Figure 3.7], and strong co-localization can also occur between RGNEF and TDP-43 [Figure 3.6]. The finding that RGNEF and FUS/TLS can be co-localized in NCIs suggests that they may be parts of the same pathogenic mechanism. Another possibility is that the sequestration of these proteins into filamentous inclusions within the cell is a coping mechanism
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for another cellular injury that may ultimately be leading to MN death. Similarly, the co-localization between RGNEF and TDP-43 suggests that these 2 proteins may be parts of a similar pathogenic mechanism, or that these inclusions represent a coping mechanism activated upon cellular injury. Important to note, too, is the fact that not all areas of an inclusion are necessarily labeled with each marker. Examples of this can be seen either in 
Figure 3.6 or Figure 3.7, where there are portions of the TDP-43 and FUS/TLS inclusions, respectively, in addition to what is sequestered with RGNEF. This raises the possibility that the aberrant expression of RNA binding proteins is contributing to cell death via a convergent mechanism, but they may also be acting individually in some instances. Regardless of the mechanism of whether or not these inclusions do contribute to the pathogenicity of ALS, they do aggregate, and are certainly part of the pathology of ALS. This raises the question of what upstream trigger is causing RNA binding protein sequestration, and if this trigger may be the insult that has an early role in disease pathogenesis.
Finally, the observation that RGNEF is not expressed in active or inactive glial cells suggests that it does not play a role in the process of neuroinflammation. As mentioned, neuroinflammation is a normal aspect of innate immunity within the nervous system, and it has been shown to be increased in ALS. The priming and subsequent activation of astrocytes and microglia is evidence that this is the case, but the lack of RGNEF association suggests no role for RGNEF in this process.
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Taken together, this study has, for the first time, characterized the intraneuronal expression of RGNEF. We have determined that RGNEF can be co-localized with translationally active polysomes within healthy tissues in a coarse granular expression pattern, and that a uniform cytoplasmic presentation is also a normal presentation. Importantly, we have shown strong evidence that RGNEF NCls can be targeted for degradation within MNs, which is evidence that RGNEF may be involved in ALS pathogenesis. Lastly, the observation that RGNEF-positive NCIs can be co-localized with FUS/TLS and TDP-43-positive NCls raises exciting possibilities for future work focusing on the role of RGNEF in ALS. This work provides strong reinforcement to the hypothesis that ALS is in fact a disease of altered RNA metabolism, as opposed to a disease of the misregulation of a single RNA binding protein.
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Chapter 4: General Discussion and Conclusions
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I have tested the hypothesis that all variants o f  A L S  are pathologically  
distinct and can be differentiated by spinal cord pathology using a panel o f  
contem porary ALS-associated m arkers. In the process of testing this hypothesis, I have made several key observations, including:
• That p62 is a more robust immunohistochemical marker of proteasome-mediated degradation in ALS tissues than ubiquitin;• That all variants of ALS can be characterized by the aberrant expression of RNA binding proteins;• That the only pathologically distinct variant of ALS is mtSODl-ALS, which is characterized by a unique protein expression pattern;• That optineurin NCI formation is not a pathological marker of any variant of ALS;• That RGNEF-positive NCIs are observed in all variants of ALS with the exception of mtSODl-ALS, and that these inclusions can be co-localized with ubiquitin and p62; and,• That RGNEF co-localizes with other ALS-associated, RNA binding proteins including TDP-43 and FUS/TLS in NCIs.
This is the first comprehensive study to analyze the expression of such a large group of ALS-associated proteins across a panel of ALS cases encompassing most of the known variants of ALS. My findings are unique and will have significant implications for our understanding of the pathogenesis of ALS. Beyond this, however, they also have direct clinical implications in the field of
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neuropathology as it relates to ALS diagnosis confirmation and the identification of novel cases of fALS.
There are several important implications to the finding that mtSODl-ALS is a pathologically unique variant of ALS. First, this finding ties together pathological observations from other researchers. Other less comprehensive studies have noted disparity between mtSODl-ALS and other single variants of the disease, but never has a study been designed to determine the existence of a pathologically unique variant of ALS. Second, although a toxic gain-of-function for mtSODl is the acquisition of RNA binding properties [destabilizing NFL mRNA], my findings raise the question of whether mtSODl can act completely independently of any other RNA binding protein in carrying out this aberrant function. With this question raised, as more work is done into the pathophysiology of ALS, it may be possible that different therapeutic targets could be designed to target different variants of the disease.
Critical to note is the standard practice for neuropathologists at the autopsy of an ALS case, which includes the application of a minimal immunohistochemical panel in order to confirm diagnosis. Never before has immunohistochemical evidence been presented that will give neuropathologists probable cause that they may be dealing with a case of mtSODl-ALS. With mtSODl-ALS being the most commonly seen type of fALS, the finding of p62- positive NCls that are negative for the non-mtSODl RNA binding proteins
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should lead to genotypic analysis in an effort to identify new families that may be prone to fALS.
There were several other objectives met in the process of determining the unique characteristics of mtSODl-ALS. Firstly, I observed that p62 is a more consistent marker of proteasome protein degradation than is ubiquitin. There have been many indications from the literature that p62 may be a more robust marker of the ubiquitin-proteasome system, although the claim has never been made explicitly (Shin, 1998; Mizuno et a l, 2006). Immunohistochemical expression of ubiquitin across the panel studied in this thesis proved more difficult than expression of p62, which resulted in a more precise expression pattern than ubiquitin and highly intense chromogen deposition.
I have also confirmed that ALS can be characterized by the aberrant expression of RNA binding proteins, providing strong support for the hypothesis that ALS is a disease of altered RNA metabolism. Given the main conclusion from this thesis, the most important observation is that altered RNA binding protein expression characterizes all variants of ALS, including mtSODl- ALS. Although TDP-43, FUS/TLS, and RGNEF NCIs were not evident in mtSODl- ALS cases, mutations in SOD1 have been reported to confer RNA binding properties on the protein (Ge et a l, 2005; Lu et a l, 2007; Li et a l, 2009), and more recent studies have reported the ability of mtSODl to sequester key regulatory RNA binding proteins (Lu et a l, 2009). Given these findings and the knowledge that SOD1 can form cytoplasmic aggregates in mtSODl-ALS cases,
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the conclusion can be drawn that ALS is a disease of altered RNA metabolism characterized by an aberrant expression of RNA binding proteins.
Finally, chapter 2 of this thesis presented evidence that the pathological expression of optineurin that has been reported amongst familial variants of ALS in Japan is not evident in either the sALS or fALS cases of our panel that bear no known mutations (Maruyama et al., 2010). This suggests that alterations in optineurin expression or function are likely not contributors to the pathogenesis of ALS. This observation is consistent with recent studies [Hortobagyi et al., 2011; Millecamps et al., 2011; Sugihara et a l, 2011). The finding that optineurin pathology is not a consistent feature of either sALS or fALS is important because of initial interest in the development of mtOPTN animal models of ALS, in addition to interest in the development of NF-k B inhibitors being used as a possible treatment in ALS.
There were also several important findings in Chapter 3. Due to the novelty of RGNEF, it was first imperative to characterize its normal expression pattern. Once this was established, it became evident that RGNEF-positive NCls were present in ALS cases, but never in controls. Importantly, RGNEF- immunoreactive NCIs could also be ubiquitin and p62 positive, providing evidence that RGNEF-positive NCIs are targeted for degradation via the proteasome degradation system. The finding is also significant because it provides yet another RNA binding protein that is both differentially expressed in ALS, but also directly involved in NFL mRNA metabolism. A similar
171
observation regarding the first-discovered of these proteins (Arai et al., 2006; Neumann et al., 2006), TDP-43, created a frenzied research focus surrounding ALS being a TDP-43 proteinopathy. This was followed with the labeling of all non-nuclear TDP-43 immunostaining as "pathological” in ALS. Similar interest was generated by the finding that FUS/TLS-positive NCIs could also be ubiquitinated in ALS cases, but never in healthy controls (Deng e ta l, 2010). We expect that our observations regarding the deposition of RGNEF immunoreactive aggregates that are also ubiquitinated across all non-mtSODl variants of ALS will generate similar interest. More critical, however, is the finding that RGNEF is the first known link between an RNA binding protein that is known to form ubiquitin and p62-positive NCIs in ALS that is also a central molecule in a cell signaling pathway.
Additionally, other important findings from Chapter 3 include the co­localization of RGNEF with both FUS/TLS and TDP-43 immunoreactive NCIs. This is not minor, but rather a very high degree of co-localization between RGNEF and FUS/TLS, as well as between RGNEF and TDP-43. This observation suggests that each of these 3 RNA binding proteins may be sequestered into the same degradative bodies as they await proteasome degradation. It is tempting to hypothesize that this sequestration is into RNA granules that are polymerized into skein-like and aggregate formations. Note also that the co-localization is not absolute as there are clear examples provided where RGNEF forms skeins independent of its association with either TDP-43 or FUS/TLS. This might
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suggest that there are additional proteins yet to be defined that will also co­localize with RGNEF.
Implications and Future Directions
This work has significant implications with respect to the future of ALS research within my lab and the field in general. First of all, as discussed, it has provided evidence that mtSODl-ALS is pathologically a distinct variant of ALS. It is my hope that this finding will be applied in neuropathologists’ practice in an effort to identify novel families that may be affected by ALS 1.
It is also crucial, however, to gain a more thorough understanding of the upstream causes of ALS so that the problems can be addressed before the aberrant biological processes manifest themselves as insoluble protein deposits. Evidence presented in this thesis suggests that the upstream events may indeed be interactions between RNA and proteins.
With respect to the future directions surrounding RGNEF, there are multiple avenues that could be pursued. Firstly, it will be important to determine whether mutations may be harboured within RGNEF that are associated with ALS. As ALS-associated mutations were discovered within 
TARDBP and FUS/TLS following the finding of similar intraneuronal pathology, it will be interesting to see if such mutations exist within RGNEF. Secondly, we need to understand how RGNEF-mediated RhoA signaling cascades may be
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altered in ALS, and how they may contribute to the misregulation of RNA and ultimately, ALS pathogenesis. Finally, and perhaps of greatest important to the field of ALS research, will be the need to critically examine the relationship between RGNEF, TDP-43, and FUS/TLS. The possibility of these 3 proteins contributing to ALS pathogenesis concomitantly is an intriguing one, and lends further support to the hypothesis that ALS is a disease of altered RNA metabolism characterized by aberrant expression of RNA binding proteins. It also clearly illustrates the fallacy in defining ALS as an "-opathy” of any single RNA binding protein.
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